JPS6145989B2 - - Google Patents
Info
- Publication number
- JPS6145989B2 JPS6145989B2 JP55018385A JP1838580A JPS6145989B2 JP S6145989 B2 JPS6145989 B2 JP S6145989B2 JP 55018385 A JP55018385 A JP 55018385A JP 1838580 A JP1838580 A JP 1838580A JP S6145989 B2 JPS6145989 B2 JP S6145989B2
- Authority
- JP
- Japan
- Prior art keywords
- tetrahydro
- furanyl
- methylene
- pyranyl
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- -1 benzyloxyethyl Chemical group 0.000 claims description 76
- 150000001875 compounds Chemical class 0.000 claims description 38
- 229910052736 halogen Inorganic materials 0.000 claims description 21
- 150000002367 halogens Chemical class 0.000 claims description 21
- 125000000217 alkyl group Chemical group 0.000 claims description 19
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 125000001424 substituent group Chemical group 0.000 claims description 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
- 125000003545 alkoxy group Chemical group 0.000 claims description 11
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 claims description 10
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 8
- 125000003342 alkenyl group Chemical group 0.000 claims description 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 6
- 150000007522 mineralic acids Chemical group 0.000 claims description 6
- 150000007524 organic acids Chemical group 0.000 claims description 6
- 229910052783 alkali metal Inorganic materials 0.000 claims description 5
- 229910001923 silver oxide Inorganic materials 0.000 claims description 5
- 150000001340 alkali metals Chemical class 0.000 claims description 4
- 150000003378 silver Chemical group 0.000 claims description 3
- 229910052709 silver Inorganic materials 0.000 claims description 3
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 17
- 239000005977 Ethylene Substances 0.000 description 17
- 206010028980 Neoplasm Diseases 0.000 description 17
- 230000015572 biosynthetic process Effects 0.000 description 14
- 238000003786 synthesis reaction Methods 0.000 description 14
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 238000000921 elemental analysis Methods 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 229940070818 glycyrrhizate Drugs 0.000 description 6
- 238000002513 implantation Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical class OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000001093 anti-cancer Effects 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- VGERIUAROHSEAN-UHFFFAOYSA-M ethenyl-methyl-(oxolan-2-yl)sulfanium iodide Chemical compound [I-].C=C[S+](C)C1OCCC1 VGERIUAROHSEAN-UHFFFAOYSA-M 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 5
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 4
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical class S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- 239000004378 Glycyrrhizin Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 150000001450 anions Chemical class 0.000 description 4
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 4
- 229960004949 glycyrrhizic acid Drugs 0.000 description 4
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 4
- 235000019410 glycyrrhizin Nutrition 0.000 description 4
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000011664 nicotinic acid Substances 0.000 description 4
- 235000001968 nicotinic acid Nutrition 0.000 description 4
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- HJRJRUMKQCMYDL-UHFFFAOYSA-N 1-chloro-2,4,6-trinitrobenzene Chemical compound [O-][N+](=O)C1=CC([N+]([O-])=O)=C(Cl)C([N+]([O-])=O)=C1 HJRJRUMKQCMYDL-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- OMNLFDHAIDKYNY-UHFFFAOYSA-M CC1=CC=C(C=C1)S(=O)(=O)[O-].C=CC[S+](CC)C1OCCCC1 Chemical compound CC1=CC=C(C=C1)S(=O)(=O)[O-].C=CC[S+](CC)C1OCCCC1 OMNLFDHAIDKYNY-UHFFFAOYSA-M 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- PPQNQXQZIWHJRB-UHFFFAOYSA-N Methylcholanthrene Chemical compound C1=CC=C2C3=CC4=CC=C(C)C(CC5)=C4C5=C3C=CC2=C1 PPQNQXQZIWHJRB-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 208000006268 Sarcoma 180 Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229940127204 compound 29 Drugs 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- NPOMSUOUAZCMBL-UHFFFAOYSA-N dichloromethane;ethoxyethane Chemical compound ClCCl.CCOCC NPOMSUOUAZCMBL-UHFFFAOYSA-N 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- VUQUOGPMUUJORT-UHFFFAOYSA-N methyl 4-methylbenzenesulfonate Chemical compound COS(=O)(=O)C1=CC=C(C)C=C1 VUQUOGPMUUJORT-UHFFFAOYSA-N 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 230000004565 tumor cell growth Effects 0.000 description 3
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 2
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- WEXPVGCBWSDOPT-UHFFFAOYSA-N 3-methylidene-2-methylsulfanyloxolane Chemical compound CSC1OCCC1=C WEXPVGCBWSDOPT-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-M 9-cis,12-cis-Octadecadienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC([O-])=O OYHQOLUKZRVURQ-HZJYTTRNSA-M 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- RGYWUAMSFYMAPJ-UHFFFAOYSA-N CSC1OCCCC1=C Chemical compound CSC1OCCCC1=C RGYWUAMSFYMAPJ-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- DZJVQTRNBDDBRR-UHFFFAOYSA-M S(=O)(=O)([O-])C1=CC=C(C)C=C1.C=C[S+](C)C1OCCCC1 Chemical compound S(=O)(=O)([O-])C1=CC=C(C)C=C1.C=C[S+](C)C1OCCCC1 DZJVQTRNBDDBRR-UHFFFAOYSA-M 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 229940022663 acetate Drugs 0.000 description 2
- GANYMSDHMBJFIL-UHFFFAOYSA-N acetonitrile;ethoxyethane Chemical compound CC#N.CCOCC GANYMSDHMBJFIL-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 210000000628 antibody-producing cell Anatomy 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 229940072107 ascorbate Drugs 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 description 2
- 229940050390 benzoate Drugs 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- QSKWJTXWJJOJFP-UHFFFAOYSA-N chloroform;ethoxyethane Chemical compound ClC(Cl)Cl.CCOCC QSKWJTXWJJOJFP-UHFFFAOYSA-N 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- IGCABUUAHFPPLP-UHFFFAOYSA-N ethenyl-methyl-(oxolan-2-yl)sulfanium Chemical compound C=C[S+](C)C1OCCC1 IGCABUUAHFPPLP-UHFFFAOYSA-N 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 235000011087 fumaric acid Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 229940001447 lactate Drugs 0.000 description 2
- 229940049918 linoleate Drugs 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- DFACHZBEUINJOO-UHFFFAOYSA-M methylene(tetrahydro-2-furanyl)dimethylsulfonium picrylsulfonate Chemical compound C[S+](C)(=C)C1CCCO1.[O-][N+](=O)C1=CC([N+]([O-])=O)=C(S([O-])(=O)=O)C([N+]([O-])=O)=C1 DFACHZBEUINJOO-UHFFFAOYSA-M 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 229940049964 oleate Drugs 0.000 description 2
- 235000021313 oleic acid Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 239000006215 rectal suppository Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- JUDUFOKGIZUSFP-UHFFFAOYSA-M silver;4-methylbenzenesulfonate Chemical compound [Ag+].CC1=CC=C(S([O-])(=O)=O)C=C1 JUDUFOKGIZUSFP-UHFFFAOYSA-M 0.000 description 2
- AJVTWWKCZSXDMP-UHFFFAOYSA-M silver;n-cyclohexylsulfamate Chemical compound [Ag+].[O-]S(=O)(=O)NC1CCCCC1 AJVTWWKCZSXDMP-UHFFFAOYSA-M 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- ITOFPJRDSCGOSA-KZLRUDJFSA-N (2s)-2-[[(4r)-4-[(3r,5r,8r,9s,10s,13r,14s,17r)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H](CC[C@]13C)[C@@H]2[C@@H]3CC[C@@H]1[C@H](C)CCC(=O)N[C@H](C(O)=O)CC1=CNC2=CC=CC=C12 ITOFPJRDSCGOSA-KZLRUDJFSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 1
- FZQXMGLQANXZRP-UHFFFAOYSA-N 1-(3,4-dimethoxyphenyl)-3-(3-imidazol-1-ylpropyl)thiourea Chemical compound C1=C(OC)C(OC)=CC=C1NC(=S)NCCCN1C=NC=C1 FZQXMGLQANXZRP-UHFFFAOYSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- MPPPKRYCTPRNTB-UHFFFAOYSA-N 1-bromobutane Chemical compound CCCCBr MPPPKRYCTPRNTB-UHFFFAOYSA-N 0.000 description 1
- UWLHSHAHTBJTBA-UHFFFAOYSA-N 1-iodooctane Chemical compound CCCCCCCCI UWLHSHAHTBJTBA-UHFFFAOYSA-N 0.000 description 1
- AHCJTMBRROLNHV-UHFFFAOYSA-N 1-methylsulfanyloctane Chemical compound CCCCCCCCSC AHCJTMBRROLNHV-UHFFFAOYSA-N 0.000 description 1
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- QFPDPEMPFAFMLO-UHFFFAOYSA-N 2-chloro-3-methylideneoxane Chemical compound ClC1OCCCC1=C QFPDPEMPFAFMLO-UHFFFAOYSA-N 0.000 description 1
- JTWVYRJNRGTBDP-UHFFFAOYSA-N 2-ethylsulfanyl-3-methylideneoxane Chemical compound C(C)SC1OCCCC1=C JTWVYRJNRGTBDP-UHFFFAOYSA-N 0.000 description 1
- FEXFEHVMYWGPSJ-UHFFFAOYSA-N 2-ethylsulfanyloxane Chemical compound CCSC1CCCCO1 FEXFEHVMYWGPSJ-UHFFFAOYSA-N 0.000 description 1
- GUKWDEUAVFIVHF-UHFFFAOYSA-N 2-ethylsulfanyloxolane Chemical compound CCSC1CCCO1 GUKWDEUAVFIVHF-UHFFFAOYSA-N 0.000 description 1
- AGVXVNUUQRAKNA-UHFFFAOYSA-N 2-methylsulfanyloxane Chemical compound CSC1CCCCO1 AGVXVNUUQRAKNA-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- BGAJNPLDJJBRHK-UHFFFAOYSA-N 3-[2-[5-(3-chloro-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-3-methyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]propanoic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C1=NN=C(N2C(=C3CN(CCC(O)=O)CCC3=N2)C)S1 BGAJNPLDJJBRHK-UHFFFAOYSA-N 0.000 description 1
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 1
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- NHFPMWWZGDRUCI-UHFFFAOYSA-M C(C(O)C)(=O)[O-].C=C[S+](C)C1OCCC1 Chemical compound C(C(O)C)(=O)[O-].C=C[S+](C)C1OCCC1 NHFPMWWZGDRUCI-UHFFFAOYSA-M 0.000 description 1
- SXFFMAKIQPFSFR-UHFFFAOYSA-N C(CCC)SC1OCCC1=C Chemical compound C(CCC)SC1OCCC1=C SXFFMAKIQPFSFR-UHFFFAOYSA-N 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- PZCUFGNFXBOHSK-UHFFFAOYSA-N CC1=CC=C(C=C1)S(=O)(=O)[O-].C=C(CCCCCCCCC)[SH+]CC1OCCC1 Chemical compound CC1=CC=C(C=C1)S(=O)(=O)[O-].C=C(CCCCCCCCC)[SH+]CC1OCCC1 PZCUFGNFXBOHSK-UHFFFAOYSA-N 0.000 description 1
- UEWITKWOWSCBIG-UHFFFAOYSA-N CCCSC1OCCC1=C Chemical compound CCCSC1OCCC1=C UEWITKWOWSCBIG-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- PLUBXMRUUVWRLT-UHFFFAOYSA-N Ethyl methanesulfonate Chemical compound CCOS(C)(=O)=O PLUBXMRUUVWRLT-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- XWAWESVQCQCMDL-UHFFFAOYSA-N S(N)(OC1CCCCC1)(=O)=O.C=C[S+](C)C1OCCC1 Chemical compound S(N)(OC1CCCCC1)(=O)=O.C=C[S+](C)C1OCCC1 XWAWESVQCQCMDL-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 1
- HCGGWJQCIWZFRP-UHFFFAOYSA-N [I-].C=C(CCCCCCCCC)[SH+]CC1OCCC1 Chemical compound [I-].C=C(CCCCCCCCC)[SH+]CC1OCCC1 HCGGWJQCIWZFRP-UHFFFAOYSA-N 0.000 description 1
- WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- 229940008075 allyl sulfide Drugs 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003849 aromatic solvent Substances 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- AQNQQHJNRPDOQV-UHFFFAOYSA-N bromocyclohexane Chemical compound BrC1CCCCC1 AQNQQHJNRPDOQV-UHFFFAOYSA-N 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- QYJXDIUNDMRLAO-UHFFFAOYSA-N butyl 4-methylbenzenesulfonate Chemical compound CCCCOS(=O)(=O)C1=CC=C(C)C=C1 QYJXDIUNDMRLAO-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- NEHMKBQYUWJMIP-NJFSPNSNSA-N chloro(114C)methane Chemical compound [14CH3]Cl NEHMKBQYUWJMIP-NJFSPNSNSA-N 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000003493 decenyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 229910000043 hydrogen iodide Inorganic materials 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 229940018158 hydroxypropylcellulose 5 mg Drugs 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- PCEBAZIVZVIQEO-UHFFFAOYSA-N iodocyclopentane Chemical compound IC1CCCC1 PCEBAZIVZVIQEO-UHFFFAOYSA-N 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 229940080428 lactose 200 mg Drugs 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- CAAULPUQFIIOTL-UHFFFAOYSA-N methyl dihydrogen phosphate Chemical compound COP(O)(O)=O CAAULPUQFIIOTL-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- MBABOKRGFJTBAE-UHFFFAOYSA-N methyl methanesulfonate Chemical compound COS(C)(=O)=O MBABOKRGFJTBAE-UHFFFAOYSA-N 0.000 description 1
- VQSRKMNBWMHJKY-YTEVENLXSA-N n-[3-[(4ar,7as)-2-amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluorophenyl]-5-methoxypyrazine-2-carboxamide Chemical compound C1=NC(OC)=CN=C1C(=O)NC1=CC=C(F)C([C@@]23[C@@H](CN(C2)C=2N=CC(F)=CN=2)CSC(N)=N3)=C1 VQSRKMNBWMHJKY-YTEVENLXSA-N 0.000 description 1
- SNMVRZFUUCLYTO-UHFFFAOYSA-N n-propyl chloride Chemical compound CCCCl SNMVRZFUUCLYTO-UHFFFAOYSA-N 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- BKUGMZHCBXZVJB-UHFFFAOYSA-N nonyl 4-methylbenzenesulfonate Chemical compound CCCCCCCCCOS(=O)(=O)C1=CC=C(C)C=C1 BKUGMZHCBXZVJB-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000004344 phenylpropyl group Chemical group 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- JTTWNTXHFYNETH-UHFFFAOYSA-N propyl 4-methylbenzenesulfonate Chemical compound CCCOS(=O)(=O)C1=CC=C(C)C=C1 JTTWNTXHFYNETH-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- NCGJACBPALRHNG-UHFFFAOYSA-M sodium;2,4,6-trinitrobenzenesulfonate Chemical compound [Na+].[O-][N+](=O)C1=CC([N+]([O-])=O)=C(S([O-])(=O)=O)C([N+]([O-])=O)=C1 NCGJACBPALRHNG-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-O sulfonium Chemical compound [SH3+] RWSOTUBLDIXVET-UHFFFAOYSA-O 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- MCOWGUNDBBHKAM-UHFFFAOYSA-N thiohypoiodous acid Chemical compound IS MCOWGUNDBBHKAM-UHFFFAOYSA-N 0.000 description 1
- 125000005490 tosylate group Chemical group 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Furan Compounds (AREA)
- Pyrane Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
æ¬çºæã¯æ°èŠãªã¹ã«ãããŠã ååç©åã³ãã®è£œ
é æ³ã«é¢ããã æ¬çºæã®ã¹ã«ãããŠã ååç©ã¯äžè¬åŒ ïŒåŒäžR1ãR2ã¯ã¢ã«ãã«ãã·ã¯ãã¢ã«ãã«ãã¢ã«
ã±ãã«ããã³ãŒã³ç°äžã«çœ®æåºãšããŠã¢ã«ãã«ã
ã¢ã«ã³ãã·åã¯ããã²ã³ãæããããšã®ããã¢ã©
ã«ãã«ã眮æåºãšããŠã¢ã«ãã«ãã¢ã«ã³ãã·åã¯
ããã²ã³ãæããããšã®ããããšãã«åã¯ãã³ãŸ
ã€ããã·ãšãã«ãY1ã¯ããã²ã³ãç¡æ©é žæ®åºå
ã¯ææ©é žæ®åºãïœã¯ïŒãïŒã®æŽæ°ãïœã¯ïŒãïŒã®
æŽæ°ã瀺ãïŒã§è¡šããããã äžèšäžè¬åŒïŒïŒã®çœ®æåºR1ãR2ã«ãããŠã¢
ã«ãã«ã®äŸãšããŠã¯ççŽ æ°ïŒã10ã®ã¢ã«ãã«ãäŸ
ãã°ã¡ãã«ããšãã«ããããã«ãããã«ãããã·
ã«ããã·ã«çããã·ã¯ãã¢ã«ãã«ã®äŸãšããŠã¯ç
çŽ æ°ïŒãïŒã®ã·ã¯ãã¢ã«ãã«ãäŸãã°ã·ã¯ããã³
ãã«ãã·ã¯ãããã·ã«ãã·ã¯ããªã¯ãã«çããã¢
ã«ã±ãã«ã®äŸãšããŠã¯ççŽ æ°ïŒã10ã®ã¢ã«ã±ã
ã«ãäŸãã°ããã«ãã¢ãªã«ãããããã«ãããã»
ãã«ããã»ãã«çããã¢ã©ã«ãã«ã®äŸãšããŠã¯ç
çŽ æ°ïŒã10ã®ã¢ã©ã«ãã«ãäŸãã°ããã³ãžã«ãã
ãšããã«ãããšãã«ãããã«çãæããããšãã§
ããæŽã«äžèšã¢ã©ã«ãã«åã³ããšãã«ã¯ãã³ãŒã³
ç°ã«ïŒåã¯ïŒåã®çœ®æåºãäŸãã°ãççŽ æ°ïŒãïŒ
ã®ã¢ã«ãã«ãççŽ æ°ïŒãïŒã®ã¢ã«ã³ãã·ãæãã¯
ããã²ã³çã®çœ®æåºãæããŠããŠãè¯ãããŸã
Y1ã®äŸãšããŠã¯å¡©çŽ ãèçŽ ãæ²çŽ çã®ããã²
ã³ããã¹ããšãŒãããã·ã¬ãŒãããã¯ãªã«ã¹ã«ã
ããŒãããã¬ãšãŒããããããŒããããã¬ãŒãã
ã©ã¯ããŒããã¿ãŒãã¬ãŒããã¢ã¹ã³ã«ããŒãããª
ãã¬ãŒãããªã¬ãšãŒããã¢ã»ããŒãããã³ãŸãšãŒ
ãããã³ãããŒããã·ã¯ãããã·ã«ã¹ã«ãã¢ã¡ãŒ
ããã°ãªãã«ãªããšãŒããã¡ã¿ã³ã¹ã«ãããŒãã
ãã©ã¢ããšãŒãçã®ç¡æ©é žæ®åºåã³ææ©é žæ®åºã
æããããšãã§ããã æ¬çºæã¹ã«ãããŠã ååç©ã¯çäœã®å ç«èœã亢
é²ããäœçšãæãã¯å¶çäœçšçãæãã極ããŠæ
çšã§ããã äžèšäžè¬åŒïŒïŒã§è¡šããããæ¬çºæååç©ã®
äŸãšããŠã¯äžèšã®ãããªååç©ãæããããšãã§
ããã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ã¡ãã«ã¹ã«ãããŠã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã¡
ãã«ããã«ã¹ã«ãããŠã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã¡
ãã«ãã·ã«ã¹ã«ãããŠã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã¡
ãã«ã·ã¯ããã³ãã«ã¹ã«ãããŠã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã¡
ãã«ãã³ãžã«ã¹ã«ãããŠã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã¡
ãã«ããšãã«ã¹ã«ãããŠã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã¡
ãã«ãã³ãŸã€ããã·ãšãã«ã¹ã«ãããŠã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ãããã«ã¹ã«ãããŠã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã
ããã«ãã³ãã«ã¹ã«ãããŠã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã
ããã«ããã·ã«ã¹ã«ãããŠã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ãã³ãžã«ã¹ã«ãããŠã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ã¡ãã«ã¹ã«ãããŠã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã¡
ãã«ããšããã«ã¹ã«ãããŠã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ãšãã«ã¹ã«ãããŠã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãš
ãã«ã¢ãªã«ã¹ã«ãããŠã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãš
ãã«ãããã«ã¹ã«ãããŠã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã
ãã·ã«ãªã¯ãã«ã¹ã«ãããŠã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãš
ãã«ã·ã¯ãããã·ã«ã¹ã«ãããŠã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ã¡ãã«ã¹ã«ãããŠã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã¡
ãã«ããã«ã¹ã«ãããŠã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã¡
ãã«ãªã¯ãã«ã¹ã«ãããŠã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã¡
ãã«âïœâã¡ãã«ããšããã«ã¹ã«ãããŠã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãš
ãã«ã·ã¯ããã³ãã«ã¹ã«ãããŠã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãš
ãã«ã·ã¯ãããã·ã«ã¹ã«ãããŠã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã
ããã«ãªã¯ãã«ã¹ã«ãããŠã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ããã·ã«ã¹ã«ãããŠã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ãã³ãžã«ã¹ã«ãããŠã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ã·ã¯ãããã·ã«ã¹ã«ãããŠã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ã¡ãã«ã¹ã«ãããŠã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã¡
ãã«âïŒâïŒïœâã¡ããã·ããšãã«ïŒãããã«ã¹
ã«ãããŠã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ãšãã«ã¹ã«ãããŠã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãš
ãã«âïœâã¯ãã«ããšãã«ã¹ã«ãããŠã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ãããã«ã¹ã«ãããŠã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã
ããã«ããšããã«ã¹ã«ãããŠã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ããã«ã¹ã«ãããŠã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ããã·ã«ã¹ã«ãããŠã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ãã³ãžã«ã¹ã«ãããŠã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãš
ãã«ããã·ã«ã¹ã«ãããŠã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãžã¡ãã«ã¹ã«ãããŠã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒã¡ãã«ãããã«ã¹ã«ãããŠã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒã¡ãã«ããã«ã¹ã«ãããŠã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãšãã«ãã·ã«ã¹ã«ãããŠã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãšãã«âïœâã¯ãã«ãã³ãžã«ã¹ã«ãããŠã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãžããã«ã¹ã«ãããŠã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒããã«âïœâã¡ããã·ããšãã«ã¹ã«ãããŠã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒããã·ã«ã·ã¯ããã³ãã«ã¹ã«ãããŠã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒããã·ã«ã·ã¯ãããã·ã«ã¹ã«ãããŠã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒããã·ã«ãã³ãžã«ã¹ã«ãããŠã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãžãã³ãžã«ã¹ã«ãããŠã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãžããšããã«ã¹ã«ãããŠã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãžããšãã«ã¹ã«ãããŠã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒããšãã«ãã³ãžã«ã¹ã«ãããŠã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãžã¡ãã«ã¹ã«ãããŠã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãžãšãã«ã¹ã«ãããŠã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãšãã«ãããã«ã¹ã«ãããŠã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãšãã«ãªã¯ãã«ã¹ã«ãããŠã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãžãããã«ã¹ã«ãããŠã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãžããã«ã¹ã«ãããŠã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒããã«ã·ã¯ãããã·ã«ã¹ã«ãããŠã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãžãã·ã«ã¹ã«ãããŠã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãžã·ã¯ããã³ãã«ã¹ã«ãããŠã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒã·ã¯ããã³ãã«ã·ã¯ãããã·ã«ã¹ã«ãããŠã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒã·ã¯ãããã·ã«ããšããã«ã¹ã«ãããŠã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãžãã³ãžã«ã¹ã«ãããŠã çã®ã¹ã«ãããŠã ååç©ã®ã¯ãã©ã€ããã¢ã€ãªã
ã€ãããããã€ãããã¹ããšãŒãããã·ã¬ãŒãã
ãã¯ãªã«ã¹ã«ãããŒãããã¬ãšãŒããããããŒ
ããããã¬ãŒããã©ã¯ããŒããã¿ãŒãã¬ãŒããã¢
ã¹ã³ã«ããŒãããªãã¬ãŒãããªã¬ãšãŒããã¢ã»ã
ãŒãããã³ãŸãšãŒãããã³ãããŒããã·ã¯ããã
ã·ã«ã¹ã«ãã¢ã¡ãŒããã°ãªãã«ãªããšãŒããã¡ã¿
ã³ã¹ã«ãããŒãããã©ãã¢ãšãŒãçãæããã
ãã äžè¬åŒïŒïŒã§è¡šããããæ¬çºæååç©ã¯äžèš
ã®ïŒã€ã®è£œé æ³ã«ããåŸãããã ã補é æ³ïŒ¡ã äžè¬åŒ ïŒåŒäžãR1ãïœåã³ïœã¯åèšãšåäžã®æå³ãæã
ãïŒã§è¡šããããã¹ã«ãã¢ã€ãååç©ãšäžè¬åŒ
R2Y1ïŒåŒäžR2ãY1ã¯åèšãšåäžã®æå³ãæã
ãïŒã§è¡šããããååç©ãšãåå¿ãããããšã«ã
ãåŸãããã äžè¬åŒïŒïŒã§è¡šããããååç©ãšããŠã¯äŸã
ã° ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã¡
ãã«ã¹ã«ãã¢ã€ã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã
ããã«ã¹ã«ãã¢ã€ã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã
ãã«ã¹ã«ãã¢ã€ã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã
ã·ã«ã¹ã«ãã¢ã€ã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã·
ã¯ããã³ãã«ã¹ã«ãã¢ã€ã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã
ãšãã«ã¹ã«ãã¢ã€ã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã
ã³ãžã«ã¹ã«ãã¢ã€ã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã
ãšããã«ã¹ã«ãã¢ã€ã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã¡
ãã«ã¹ã«ãã¢ã€ã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãš
ãã«ã¹ã«ãã¢ã€ã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã·
ã¯ãããã·ã«ã¹ã«ãã¢ã€ã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã¢
ãªã«ã¹ã«ãã¢ã€ã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã
ãšãã«ã¹ã«ãã¢ã€ã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã¡
ãã«ã¹ã«ãã¢ã€ã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã
ãã«ã¹ã«ãã¢ã€ã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã
ãã·ã«ã¹ã«ãã¢ã€ã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã
ãšãã«ã¹ã«ãã¢ã€ã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒïœ
âã¡ãã«ããšããã«ã¹ã«ãã¢ã€ã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã¡
ãã«ã¹ã«ãã¢ã€ã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã
ãã«ã¹ã«ãã¢ã€ã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã
ã³ãžã«ã¹ã«ãã¢ã€ã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒã¡ãã«ã¹ã«ãã¢ã€ã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãšãã«ã¹ã«ãã¢ã€ã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãããã«ã¹ã«ãã¢ã€ã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãã·ã«ã¹ã«ãã¢ã€ã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒã·ã¯ãããã·ã«ã¹ã«ãã¢ã€ã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãã³ãžã«ã¹ã«ãã¢ã€ã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒã¡ãã«ã¹ã«ãã¢ã€ã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãšãã«ã¹ã«ãã¢ã€ã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãããã«ã¹ã«ãã¢ã€ã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãªã¯ãã«ã¹ã«ãã¢ã€ã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãã³ãžã«ã¹ã«ãã¢ã€ã çãæããããã äžè¬åŒïŒïŒã§è¡šããããã¹ã«ãã¢ã€ãååç©
ã¯ããããæ°èŠç©è³ªã§ããäžè¬åŒ ïŒåŒäžïœãïœã¯ãåèšãšåäžã®æå³ãæããhalã¯
ããã²ã³ã瀺ãïŒã§è¡šããããååç©ãšäžè¬åŒ R1SH ïŒïŒ ïŒåŒäžR1ã¯åèšãšåäžã®æå³ãæãïŒã§è¡šããã
ãååç©ãšããããªãŠã ãã«ãªãŠã çã®ã¢ã«ã«ãª
éå±ããããã®æ°ŽçŽ åç©ãæãã¯ããããã®æ°Žé ž
åç©ã®ååšäžã§åå¿ãããããšã«ããåæãã
ããäžè¬åŒïŒïŒã®ã¹ã«ãã¢ã€ãååç©ã®åæã®
詳现ã¯åŸèšèšèŒã®åèäŸã«ãããŠèšè¿°ããããã
äžæ¹ã®åºçºåæã§ããR2Y1ïŒR2ãY1ã¯åèšãšå
äžã®æå³ãæããïŒã§è¡šããããååç©ãšããŠã¯
äŸãã°ã¡ãã«ã¯ãã©ã€ããã¡ãã«ã¢ã€ãªãã€ãã
ãšãã«ãããã€ãããããã«ã¯ãã©ã€ããããã«
ãããã€ããã·ã¯ãããã·ã«ãããã€ããã·ã¯ã
ãã³ãã«ã¢ã€ãªãã€ããã¢ãªã«ãããã€ãããã³
ãžã«ã¯ãã©ã€ãããã³ãžã«ãããã€ãããªã¯ãã«
ã¢ã€ãªãã€ããã¡ã¿ã³ã¹ã«ãã³é žã¡ãã«ãã¡ã¿ã³
ã¹ã«ãã³é žãšãã«ããã·ã«é žã¡ãã«ããã·ã«é žã
ããã«ããã·ã«é žããã«ããã·ã«é žããã«ãã¢ã
ã¡ãã«ãªã³é žãšã¹ãã«çãæãããããæ¬åå¿ã¯
溶åªäžãæãã¯ç¡æº¶åªäžã§çŽâ30ã150â奜ãŸã
ãã¯çŽïŒã100âã§è¡ããããR2Y1ã§è¡šãããã
ååç©ã¯ã¹ã«ãã¢ã€ãååç©ïŒïŒã«å¯Ÿããéå°
é䜿çšããŠãè¯ããã奜ãŸããã¯çŽïŒãïŒåã¢ã«
䜿çšããã®ãè¯ãã溶åªã¯ã¡ã¿ããŒã«ããšã¿ããŒ
ã«ããããããŒã«çã®ã¢ã«ã³ãŒã«é¡ãã¢ã»ããã
ãªã«ããããã¡ã¿ã³ããžã¡ãã«ãã«ã ã¢ããããž
ã¡ãã«ã¹ã«ããã·ãçã®æ¥µæ§æº¶åªé¡ãã¡ãã¬ã³ã¯
ãã©ã€ãããšãã¬ã³ã¯ãã©ã€ããã¯ãããã«ã ç
ã®ããã²ã³åçåæ°ŽçŽ ããã³ãŒã³ããã«ãšã³ãã
ã·ã¬ã³çã®è³éŠæçåæ°ŽçŽ ããšãã«ãšãŒãã«ãã
ããã«ãšãŒãã«çã®ãšãŒãã«é¡ãã®ä»ãã¢ã»ã
ã³ãé ¢é žãšãã«ãšã¹ãã«ãæ°Žçã䜿çšã§ããã ã補é æ³ïŒ¢ã äžè¬åŒ ïŒåŒäžR1ãR2ãïœåã³ïœã¯åèšãšåäžã®æå³ãæ
ããã¯ããã²ã³ã瀺ãïŒã§è¡šããããã¹ã«ãã
ãŠã ããã²ãã€ããšäžè¬åŒZY2ïŒåŒäžïŒºã¯éåå
æãã¯ã¢ã«ã«ãªéå±ã瀺ããY2ã¯ïŒžãšç°ãªãã
ãã²ã³ãæãã¯ç¡æ©é žæ®åºåã¯ææ©é žæ®åºã瀺
ãïŒã§è¡šããããååç©ãšãåå¿ãããããšã«ã
ãåŸãããã äžè¬åŒïŒïŒã§è¡šããããã¹ã«ãããŠã ããã²
ãã€ãã®äŸãšããŠã¯äŸãã° ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ã¡ãã«ã¹ã«ãããŠã ã®ã¯ãã©ã€ãããããã€ãã
ã¢ã€ãªãã€ãã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ãšãã«ã¹ã«ãããŠã ã®ã¢ã€ãªãã€ãã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ã¡ãã«ã¹ã«ãããŠã ã®ã¯ãã©ã€ããã¢ã€ãªãã€
ãã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã¡
ãã«ããã«ã¹ã«ãããŠã ã¢ã€ãªãã€ãã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã¡
ãã«ããã«ã¹ã«ãããŠã ãããã€ãã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ããã«ã¹ã«ãããŠã ã¢ã€ãªãã€ãã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒã¡ãã«ã·ã¯ãããã·ã«ã¹ã«ãããŠã ãããã€
ãã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãšãã«ãããã«ã¹ã«ãããŠã ã¢ã€ãªãã€ã çãæããããã äžè¬åŒZY2ã§è¡šããããååç©ãšããŠã¯äŸã
ã°ããšãŠçŽ ãèçŽ çã®ããã²ã³ãç¡é žããªã³é žã
ã¡ã¿ãªã³é žãé ¢é žãããããªã³é žãã€ãœé ªé žãã
ã¬ã€ã³é žãããã³é žããããŒã«é žãã¯ãšã³é žãä¹³
é žãé ç³é žãã¹ãã¢ãªã³é žããªããŒã«é žããªã¬ã€
ã³é žãã¢ã¹ã³ã«ãã³é žãã·ã¯ãããã·ã«ã¹ã«ãã¢
ãã³é žãã¡ã¿ã³ã¹ã«ãã³é žããã³ãŒã³ã¹ã«ãã³
é žããã·ã«é žããã¯ãªã«ã¹ã«ãã³é žãå®æ¯éŠé žã
ãã³ãã³é žãã°ãªãã«ã¬ã·ã³é žãã°ãªãã«ãªãã³
çã®éå¡©åã¯ã¢ã«ã«ãªéå±å¡©ãæããããã¢ã«ã«
ãªéå±ãšããŠã¯äŸãã°ãããªãŠã ãã«ãªãŠã ããª
ããŠã çãæãããããäžè¬åŒïŒïŒã§è¡šããã
ãã¹ã«ãããŠã ããã²ãã€ãã¯åé¢ããŠãããªã
ãŠããããåèšè£œé æ³ã§åŸãããåå¿æ··åç©ã䜿
çšããããšãå¯èœã§ãããæ¬åå¿ã¯æº¶åªäžçŽâ30
ã150â奜ãŸããã¯çŽïŒã100âã§è¡ããããäžè¬
åŒZY2ã§è¡šããããååç©ã¯ã¹ã«ãããŠã ããã²
ãã€ãïŒïŒã«å¯Ÿããéå°é䜿çšããŠãè¯ãã奜
ãŸããã¯çŽïŒãïŒåã¢ã«éã䜿çšããã溶åªã¯å
èšè£œé æ³ïŒ¡ã®åå¿ã«äœ¿çšå¯èœãªæº¶åªã䜿çšã§ã
ãã ã補é æ³ïŒ£ã äžè¬åŒïŒïŒã§è¡šããããã¹ã«ãããŠã ååç©
ã«é žåéãåå¿ãã äžè¬åŒ ïŒåŒäžR1ãR2ãïœåã³ïœã¯åèšãšåäžã®æå³ãæ
ãããïŒã§è¡šããããã¹ã«ãããŠã æ°Žé žåç©ãç
æããããããã«åé¢ããããšãªããHY2ïŒY2ã¯
åèšãšåäžã®æå³ãæãïŒã§è¡šããããååç©ãš
ãåå¿ãããããšã«ãããæ¬çºæååç©ïŒïŒã
åŸãã åæãšããŠçšããããã¹ã«ãããŠã ååç©
ïŒïŒã®å ·äœäŸãšããŠã¯ã補é æ³ïŒ¢ã§äŸç€ºããã
ã®ã䜿çšã§ãããåãHY2ã§è¡šããããååç©ãš
ããŠã¯ããšãŠåæ°ŽçŽ ãå¡©åæ°ŽçŽ ãèåæ°ŽçŽ ãç¡
é žããªã³é žãã¡ã¿ãªã³é žãé ¢é žãããããªã³é žã
ã€ãœé ªé žããã¬ã€ã³é žãããã³é žããããŒã«é žã
ã¯ãšã³é žãä¹³é žãé ç³é žãã¹ãã¢ãªã³é žããªããŒ
ã«é žããªã¬ã€ã³é žãã¢ã¹ã³ã«ãã³é žãã·ã¯ããã
ã·ã«ã¹ã«ãã¢ãã³é žãã¡ã¿ã³ã¹ã«ãã³é žããã³ãŒ
ã³ã¹ã«ãã³é žããã·ã«é žããã¯ãªã«ã¹ã«ãã³é žã
å®æ¯éŠé žããã³ãã³é žãã°ãªãã«ã¬ã·ã³é žãã°ãª
ãã«ãªãã³çã䜿çšãããã é žåéã®äœ¿çšå²åã¯ïŒïŒã®ã¹ã«ãããŠã åå
ç©ã«å¯ŸããŠçã¢ã«ä»¥äžã§ããã°ããã奜ãŸããã¯
çŽïŒãïŒã¢ã«æ¯ã§ãããHY2ã§è¡šããããååç©
ã®äœ¿çšå²åã¯ïŒïŒã®ã¹ã«ãããŠã ååç©ã«å¯Ÿã
ãŠçã¢ã«ä»¥äžã§ããã°è¯ãã奜ãŸããã¯çŽïŒãïŒ
ã¢ã«æ¯ã§ãããåå¿æº¶åªãšããŠã¯ãåèšè£œé æ³ïŒ¡
ã®åå¿ã«äœ¿çšå¯èœãªæº¶åªã䜿çšã§ãããåãåå¿
枩床ã¯éåžžçŽâ30ã150âã奜ãŸããã¯çŽïŒã100
âã§è¡ãªããããæ¬çºæã®ã¹ã«ãããŠã ååç©ã¯
éåžžã®åé¢æ¹æ³ãäŸãã°åçµæ¶ãã«ã©ã ã¯ããã
ã°ã©ãã€ãŒçã«ãã容æã«åé¢ã§ããã æ¬çºæã®ã¹ã«ãããŠã ååç©ã¯çäœã®å ç«èœã
亢é²ãåãå¶çäœçšãæããã®ã¿ãªãããå ç«èª¿
ç¯äœçšïŒæãªãŠããäœçšïŒæ¶çé®çäœçšïŒèæ©èœ
æ¹åäœçšïŒæèªå·±å ç«äœçšïŒæã¢ã¬ã«ã®ãŒäœçšïŒ
æåæ¯äœçšïŒææé²åŸ¡äœçšïŒã¹ããã€ãå€ãå¶ç
å€çã®å¯äœçšãšããŠå ç«æå¶äœçšãæããååç©
ã®å¯äœçšé²æ¢äœçšïŒå ç«çæ³ã®è£å©äœçšïŒè¡å°æ¿
åéé»æ¢äœçšïŒçç©æé·èª¿ç¯äœçšçãæãå»è¬
åã蟲è¬ãšããŠæçšã§ããã æ¬çºæååç©ã®å»è¬ãšããŠã®æäžåœ¢æ ãšããŠã¯
æ²»çç®çã«å¿ããŠåçš®ã®åœ¢æ ãæ¡çšå¯èœã§äŸãã°
çµå£å€ã泚å°å€ãçŽè žåå€çã®ãããã§ãããã
åœæ¥è ã«å ¬ç¥æ £çšã®è£œå€æ¹æ³ã«ãã補é ã§ããã
çµå£çšåºå補å€ã調補ããå Žåã¯æ¬çºæååç©ã«
賊圢å€ãæŽã«å¿ èŠã«å¿ããŠãçµåå€ã厩解å€ãæ»
æ²¢å€ãçè²å€ãç¯å³å€ãç¯èå€çãå ããåŸãåžž
æ³ã«ãããé å€ã被èŠé å€ãé¡ç²å€ãæ£å€ãã«ã
ã»ã«å€çãäœæããããšãã§ããã çµå£æ¶²ç¶è£œå€ã調補ããå Žåã«ã¯ãæ¬çºæåå
ç©ã«ç¯å³å€ãç·©è¡å€ãå®å®åå€ãç¯èå€çãå ã
ãŠãåžžæ³ã«ããå æ液å€ãã·ãããå€ããã©ã€ã·
ãããå€çã補é ããããšãã§ããã泚å°å€ã調
補ããå Žåã¯æ¬çºæååç©ã«PH調æŽå€ãç·©è¡å€ã
å®å®åå€ãç匵åå€ãå±æ麻é å€çãæ·»å ããåžž
æ³ã«ãããç®äžãçèå ãéèå çšæ³šå°å€ã補é
ããããšãã§ãããçŽè žåè¬è£œå€ã調補ããå Žå
ã«ã¯æ¬çºæååç©ã«è³Šåœ¢å€ãæŽã«å¿ èŠã«å¿ããŠç
é¢æŽ»æ§å€çãå ããåŸåžžæ³ã«ããåå€ã補é ãã
ããšãã§ããã äžèšã®æäžåäœåœ¢æ äžã«é åãããã¹ããã¹ã«
ãããŠã ååç©ã®éã¯çç¶ã«ãããæãã¯å€åã«
ããäžå®ã§ãªãããäžè¬ã«çµå£å€ã§ã¯çŽïŒã1000
mgã泚å°å€ã§ã¯çŽ0.5ã500mgãåå€ã§ã¯çŽïŒã
1000mgãšããã®ãæãŸãããåïŒæ¥åœãã®æäžé
ãçç¶çã«å¿ãäžæŠã«ã¯æ±ºå®ã§ããªããéåžžçŽ
0.5ã5000mgãšããã®ã奜ãŸããã 次ã«æ¬çºæã«ãããŠåŸãããååç©ãè¡šïŒã«ç€º
ãã â» è¡šïŒäž TsOïŒPsãGLã¯ä»¥äžã®ã¢ããªã³ã瀺ãã TsOïŒïœâãã«ãšã³ã¹ã«ãã³é žã®ã¢ããªã³ PsïŒãã¯ãªã«ã¹ã«ãã³é žã®ã¢ããªã³ GLïŒã°ãªãã«ãªãã³ã®ã¢ããªã³ ãŸãNMRã¯DMSOâd6äžãTMSãå éšæšæºç©
質ãšããŠæž¬å®ããã
é æ³ã«é¢ããã æ¬çºæã®ã¹ã«ãããŠã ååç©ã¯äžè¬åŒ ïŒåŒäžR1ãR2ã¯ã¢ã«ãã«ãã·ã¯ãã¢ã«ãã«ãã¢ã«
ã±ãã«ããã³ãŒã³ç°äžã«çœ®æåºãšããŠã¢ã«ãã«ã
ã¢ã«ã³ãã·åã¯ããã²ã³ãæããããšã®ããã¢ã©
ã«ãã«ã眮æåºãšããŠã¢ã«ãã«ãã¢ã«ã³ãã·åã¯
ããã²ã³ãæããããšã®ããããšãã«åã¯ãã³ãŸ
ã€ããã·ãšãã«ãY1ã¯ããã²ã³ãç¡æ©é žæ®åºå
ã¯ææ©é žæ®åºãïœã¯ïŒãïŒã®æŽæ°ãïœã¯ïŒãïŒã®
æŽæ°ã瀺ãïŒã§è¡šããããã äžèšäžè¬åŒïŒïŒã®çœ®æåºR1ãR2ã«ãããŠã¢
ã«ãã«ã®äŸãšããŠã¯ççŽ æ°ïŒã10ã®ã¢ã«ãã«ãäŸ
ãã°ã¡ãã«ããšãã«ããããã«ãããã«ãããã·
ã«ããã·ã«çããã·ã¯ãã¢ã«ãã«ã®äŸãšããŠã¯ç
çŽ æ°ïŒãïŒã®ã·ã¯ãã¢ã«ãã«ãäŸãã°ã·ã¯ããã³
ãã«ãã·ã¯ãããã·ã«ãã·ã¯ããªã¯ãã«çããã¢
ã«ã±ãã«ã®äŸãšããŠã¯ççŽ æ°ïŒã10ã®ã¢ã«ã±ã
ã«ãäŸãã°ããã«ãã¢ãªã«ãããããã«ãããã»
ãã«ããã»ãã«çããã¢ã©ã«ãã«ã®äŸãšããŠã¯ç
çŽ æ°ïŒã10ã®ã¢ã©ã«ãã«ãäŸãã°ããã³ãžã«ãã
ãšããã«ãããšãã«ãããã«çãæããããšãã§
ããæŽã«äžèšã¢ã©ã«ãã«åã³ããšãã«ã¯ãã³ãŒã³
ç°ã«ïŒåã¯ïŒåã®çœ®æåºãäŸãã°ãççŽ æ°ïŒãïŒ
ã®ã¢ã«ãã«ãççŽ æ°ïŒãïŒã®ã¢ã«ã³ãã·ãæãã¯
ããã²ã³çã®çœ®æåºãæããŠããŠãè¯ãããŸã
Y1ã®äŸãšããŠã¯å¡©çŽ ãèçŽ ãæ²çŽ çã®ããã²
ã³ããã¹ããšãŒãããã·ã¬ãŒãããã¯ãªã«ã¹ã«ã
ããŒãããã¬ãšãŒããããããŒããããã¬ãŒãã
ã©ã¯ããŒããã¿ãŒãã¬ãŒããã¢ã¹ã³ã«ããŒãããª
ãã¬ãŒãããªã¬ãšãŒããã¢ã»ããŒãããã³ãŸãšãŒ
ãããã³ãããŒããã·ã¯ãããã·ã«ã¹ã«ãã¢ã¡ãŒ
ããã°ãªãã«ãªããšãŒããã¡ã¿ã³ã¹ã«ãããŒãã
ãã©ã¢ããšãŒãçã®ç¡æ©é žæ®åºåã³ææ©é žæ®åºã
æããããšãã§ããã æ¬çºæã¹ã«ãããŠã ååç©ã¯çäœã®å ç«èœã亢
é²ããäœçšãæãã¯å¶çäœçšçãæãã極ããŠæ
çšã§ããã äžèšäžè¬åŒïŒïŒã§è¡šããããæ¬çºæååç©ã®
äŸãšããŠã¯äžèšã®ãããªååç©ãæããããšãã§
ããã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ã¡ãã«ã¹ã«ãããŠã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã¡
ãã«ããã«ã¹ã«ãããŠã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã¡
ãã«ãã·ã«ã¹ã«ãããŠã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã¡
ãã«ã·ã¯ããã³ãã«ã¹ã«ãããŠã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã¡
ãã«ãã³ãžã«ã¹ã«ãããŠã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã¡
ãã«ããšãã«ã¹ã«ãããŠã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã¡
ãã«ãã³ãŸã€ããã·ãšãã«ã¹ã«ãããŠã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ãããã«ã¹ã«ãããŠã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã
ããã«ãã³ãã«ã¹ã«ãããŠã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã
ããã«ããã·ã«ã¹ã«ãããŠã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ãã³ãžã«ã¹ã«ãããŠã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ã¡ãã«ã¹ã«ãããŠã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã¡
ãã«ããšããã«ã¹ã«ãããŠã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ãšãã«ã¹ã«ãããŠã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãš
ãã«ã¢ãªã«ã¹ã«ãããŠã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãš
ãã«ãããã«ã¹ã«ãããŠã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã
ãã·ã«ãªã¯ãã«ã¹ã«ãããŠã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãš
ãã«ã·ã¯ãããã·ã«ã¹ã«ãããŠã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ã¡ãã«ã¹ã«ãããŠã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã¡
ãã«ããã«ã¹ã«ãããŠã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã¡
ãã«ãªã¯ãã«ã¹ã«ãããŠã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã¡
ãã«âïœâã¡ãã«ããšããã«ã¹ã«ãããŠã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãš
ãã«ã·ã¯ããã³ãã«ã¹ã«ãããŠã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãš
ãã«ã·ã¯ãããã·ã«ã¹ã«ãããŠã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã
ããã«ãªã¯ãã«ã¹ã«ãããŠã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ããã·ã«ã¹ã«ãããŠã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ãã³ãžã«ã¹ã«ãããŠã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ã·ã¯ãããã·ã«ã¹ã«ãããŠã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ã¡ãã«ã¹ã«ãããŠã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã¡
ãã«âïŒâïŒïœâã¡ããã·ããšãã«ïŒãããã«ã¹
ã«ãããŠã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ãšãã«ã¹ã«ãããŠã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãš
ãã«âïœâã¯ãã«ããšãã«ã¹ã«ãããŠã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ãããã«ã¹ã«ãããŠã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã
ããã«ããšããã«ã¹ã«ãããŠã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ããã«ã¹ã«ãããŠã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ããã·ã«ã¹ã«ãããŠã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ãã³ãžã«ã¹ã«ãããŠã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãš
ãã«ããã·ã«ã¹ã«ãããŠã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãžã¡ãã«ã¹ã«ãããŠã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒã¡ãã«ãããã«ã¹ã«ãããŠã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒã¡ãã«ããã«ã¹ã«ãããŠã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãšãã«ãã·ã«ã¹ã«ãããŠã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãšãã«âïœâã¯ãã«ãã³ãžã«ã¹ã«ãããŠã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãžããã«ã¹ã«ãããŠã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒããã«âïœâã¡ããã·ããšãã«ã¹ã«ãããŠã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒããã·ã«ã·ã¯ããã³ãã«ã¹ã«ãããŠã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒããã·ã«ã·ã¯ãããã·ã«ã¹ã«ãããŠã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒããã·ã«ãã³ãžã«ã¹ã«ãããŠã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãžãã³ãžã«ã¹ã«ãããŠã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãžããšããã«ã¹ã«ãããŠã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãžããšãã«ã¹ã«ãããŠã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒããšãã«ãã³ãžã«ã¹ã«ãããŠã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãžã¡ãã«ã¹ã«ãããŠã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãžãšãã«ã¹ã«ãããŠã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãšãã«ãããã«ã¹ã«ãããŠã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãšãã«ãªã¯ãã«ã¹ã«ãããŠã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãžãããã«ã¹ã«ãããŠã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãžããã«ã¹ã«ãããŠã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒããã«ã·ã¯ãããã·ã«ã¹ã«ãããŠã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãžãã·ã«ã¹ã«ãããŠã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãžã·ã¯ããã³ãã«ã¹ã«ãããŠã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒã·ã¯ããã³ãã«ã·ã¯ãããã·ã«ã¹ã«ãããŠã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒã·ã¯ãããã·ã«ããšããã«ã¹ã«ãããŠã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãžãã³ãžã«ã¹ã«ãããŠã çã®ã¹ã«ãããŠã ååç©ã®ã¯ãã©ã€ããã¢ã€ãªã
ã€ãããããã€ãããã¹ããšãŒãããã·ã¬ãŒãã
ãã¯ãªã«ã¹ã«ãããŒãããã¬ãšãŒããããããŒ
ããããã¬ãŒããã©ã¯ããŒããã¿ãŒãã¬ãŒããã¢
ã¹ã³ã«ããŒãããªãã¬ãŒãããªã¬ãšãŒããã¢ã»ã
ãŒãããã³ãŸãšãŒãããã³ãããŒããã·ã¯ããã
ã·ã«ã¹ã«ãã¢ã¡ãŒããã°ãªãã«ãªããšãŒããã¡ã¿
ã³ã¹ã«ãããŒãããã©ãã¢ãšãŒãçãæããã
ãã äžè¬åŒïŒïŒã§è¡šããããæ¬çºæååç©ã¯äžèš
ã®ïŒã€ã®è£œé æ³ã«ããåŸãããã ã補é æ³ïŒ¡ã äžè¬åŒ ïŒåŒäžãR1ãïœåã³ïœã¯åèšãšåäžã®æå³ãæã
ãïŒã§è¡šããããã¹ã«ãã¢ã€ãååç©ãšäžè¬åŒ
R2Y1ïŒåŒäžR2ãY1ã¯åèšãšåäžã®æå³ãæã
ãïŒã§è¡šããããååç©ãšãåå¿ãããããšã«ã
ãåŸãããã äžè¬åŒïŒïŒã§è¡šããããååç©ãšããŠã¯äŸã
ã° ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã¡
ãã«ã¹ã«ãã¢ã€ã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã
ããã«ã¹ã«ãã¢ã€ã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã
ãã«ã¹ã«ãã¢ã€ã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã
ã·ã«ã¹ã«ãã¢ã€ã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã·
ã¯ããã³ãã«ã¹ã«ãã¢ã€ã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã
ãšãã«ã¹ã«ãã¢ã€ã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã
ã³ãžã«ã¹ã«ãã¢ã€ã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã
ãšããã«ã¹ã«ãã¢ã€ã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã¡
ãã«ã¹ã«ãã¢ã€ã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãš
ãã«ã¹ã«ãã¢ã€ã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã·
ã¯ãããã·ã«ã¹ã«ãã¢ã€ã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã¢
ãªã«ã¹ã«ãã¢ã€ã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã
ãšãã«ã¹ã«ãã¢ã€ã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã¡
ãã«ã¹ã«ãã¢ã€ã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã
ãã«ã¹ã«ãã¢ã€ã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã
ãã·ã«ã¹ã«ãã¢ã€ã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã
ãšãã«ã¹ã«ãã¢ã€ã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒïœ
âã¡ãã«ããšããã«ã¹ã«ãã¢ã€ã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã¡
ãã«ã¹ã«ãã¢ã€ã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã
ãã«ã¹ã«ãã¢ã€ã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã
ã³ãžã«ã¹ã«ãã¢ã€ã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒã¡ãã«ã¹ã«ãã¢ã€ã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãšãã«ã¹ã«ãã¢ã€ã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãããã«ã¹ã«ãã¢ã€ã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãã·ã«ã¹ã«ãã¢ã€ã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒã·ã¯ãããã·ã«ã¹ã«ãã¢ã€ã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãã³ãžã«ã¹ã«ãã¢ã€ã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒã¡ãã«ã¹ã«ãã¢ã€ã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãšãã«ã¹ã«ãã¢ã€ã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãããã«ã¹ã«ãã¢ã€ã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãªã¯ãã«ã¹ã«ãã¢ã€ã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãã³ãžã«ã¹ã«ãã¢ã€ã çãæããããã äžè¬åŒïŒïŒã§è¡šããããã¹ã«ãã¢ã€ãååç©
ã¯ããããæ°èŠç©è³ªã§ããäžè¬åŒ ïŒåŒäžïœãïœã¯ãåèšãšåäžã®æå³ãæããhalã¯
ããã²ã³ã瀺ãïŒã§è¡šããããååç©ãšäžè¬åŒ R1SH ïŒïŒ ïŒåŒäžR1ã¯åèšãšåäžã®æå³ãæãïŒã§è¡šããã
ãååç©ãšããããªãŠã ãã«ãªãŠã çã®ã¢ã«ã«ãª
éå±ããããã®æ°ŽçŽ åç©ãæãã¯ããããã®æ°Žé ž
åç©ã®ååšäžã§åå¿ãããããšã«ããåæãã
ããäžè¬åŒïŒïŒã®ã¹ã«ãã¢ã€ãååç©ã®åæã®
詳现ã¯åŸèšèšèŒã®åèäŸã«ãããŠèšè¿°ããããã
äžæ¹ã®åºçºåæã§ããR2Y1ïŒR2ãY1ã¯åèšãšå
äžã®æå³ãæããïŒã§è¡šããããååç©ãšããŠã¯
äŸãã°ã¡ãã«ã¯ãã©ã€ããã¡ãã«ã¢ã€ãªãã€ãã
ãšãã«ãããã€ãããããã«ã¯ãã©ã€ããããã«
ãããã€ããã·ã¯ãããã·ã«ãããã€ããã·ã¯ã
ãã³ãã«ã¢ã€ãªãã€ããã¢ãªã«ãããã€ãããã³
ãžã«ã¯ãã©ã€ãããã³ãžã«ãããã€ãããªã¯ãã«
ã¢ã€ãªãã€ããã¡ã¿ã³ã¹ã«ãã³é žã¡ãã«ãã¡ã¿ã³
ã¹ã«ãã³é žãšãã«ããã·ã«é žã¡ãã«ããã·ã«é žã
ããã«ããã·ã«é žããã«ããã·ã«é žããã«ãã¢ã
ã¡ãã«ãªã³é žãšã¹ãã«çãæãããããæ¬åå¿ã¯
溶åªäžãæãã¯ç¡æº¶åªäžã§çŽâ30ã150â奜ãŸã
ãã¯çŽïŒã100âã§è¡ããããR2Y1ã§è¡šãããã
ååç©ã¯ã¹ã«ãã¢ã€ãååç©ïŒïŒã«å¯Ÿããéå°
é䜿çšããŠãè¯ããã奜ãŸããã¯çŽïŒãïŒåã¢ã«
䜿çšããã®ãè¯ãã溶åªã¯ã¡ã¿ããŒã«ããšã¿ããŒ
ã«ããããããŒã«çã®ã¢ã«ã³ãŒã«é¡ãã¢ã»ããã
ãªã«ããããã¡ã¿ã³ããžã¡ãã«ãã«ã ã¢ããããž
ã¡ãã«ã¹ã«ããã·ãçã®æ¥µæ§æº¶åªé¡ãã¡ãã¬ã³ã¯
ãã©ã€ãããšãã¬ã³ã¯ãã©ã€ããã¯ãããã«ã ç
ã®ããã²ã³åçåæ°ŽçŽ ããã³ãŒã³ããã«ãšã³ãã
ã·ã¬ã³çã®è³éŠæçåæ°ŽçŽ ããšãã«ãšãŒãã«ãã
ããã«ãšãŒãã«çã®ãšãŒãã«é¡ãã®ä»ãã¢ã»ã
ã³ãé ¢é žãšãã«ãšã¹ãã«ãæ°Žçã䜿çšã§ããã ã補é æ³ïŒ¢ã äžè¬åŒ ïŒåŒäžR1ãR2ãïœåã³ïœã¯åèšãšåäžã®æå³ãæ
ããã¯ããã²ã³ã瀺ãïŒã§è¡šããããã¹ã«ãã
ãŠã ããã²ãã€ããšäžè¬åŒZY2ïŒåŒäžïŒºã¯éåå
æãã¯ã¢ã«ã«ãªéå±ã瀺ããY2ã¯ïŒžãšç°ãªãã
ãã²ã³ãæãã¯ç¡æ©é žæ®åºåã¯ææ©é žæ®åºã瀺
ãïŒã§è¡šããããååç©ãšãåå¿ãããããšã«ã
ãåŸãããã äžè¬åŒïŒïŒã§è¡šããããã¹ã«ãããŠã ããã²
ãã€ãã®äŸãšããŠã¯äŸãã° ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ã¡ãã«ã¹ã«ãããŠã ã®ã¯ãã©ã€ãããããã€ãã
ã¢ã€ãªãã€ãã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ãšãã«ã¹ã«ãããŠã ã®ã¢ã€ãªãã€ãã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ã¡ãã«ã¹ã«ãããŠã ã®ã¯ãã©ã€ããã¢ã€ãªãã€
ãã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã¡
ãã«ããã«ã¹ã«ãããŠã ã¢ã€ãªãã€ãã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã¡
ãã«ããã«ã¹ã«ãããŠã ãããã€ãã ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ããã«ã¹ã«ãããŠã ã¢ã€ãªãã€ãã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒã¡ãã«ã·ã¯ãããã·ã«ã¹ã«ãããŠã ãããã€
ãã ããªã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãšãã«ãããã«ã¹ã«ãããŠã ã¢ã€ãªãã€ã çãæããããã äžè¬åŒZY2ã§è¡šããããååç©ãšããŠã¯äŸã
ã°ããšãŠçŽ ãèçŽ çã®ããã²ã³ãç¡é žããªã³é žã
ã¡ã¿ãªã³é žãé ¢é žãããããªã³é žãã€ãœé ªé žãã
ã¬ã€ã³é žãããã³é žããããŒã«é žãã¯ãšã³é žãä¹³
é žãé ç³é žãã¹ãã¢ãªã³é žããªããŒã«é žããªã¬ã€
ã³é žãã¢ã¹ã³ã«ãã³é žãã·ã¯ãããã·ã«ã¹ã«ãã¢
ãã³é žãã¡ã¿ã³ã¹ã«ãã³é žããã³ãŒã³ã¹ã«ãã³
é žããã·ã«é žããã¯ãªã«ã¹ã«ãã³é žãå®æ¯éŠé žã
ãã³ãã³é žãã°ãªãã«ã¬ã·ã³é žãã°ãªãã«ãªãã³
çã®éå¡©åã¯ã¢ã«ã«ãªéå±å¡©ãæããããã¢ã«ã«
ãªéå±ãšããŠã¯äŸãã°ãããªãŠã ãã«ãªãŠã ããª
ããŠã çãæãããããäžè¬åŒïŒïŒã§è¡šããã
ãã¹ã«ãããŠã ããã²ãã€ãã¯åé¢ããŠãããªã
ãŠããããåèšè£œé æ³ã§åŸãããåå¿æ··åç©ã䜿
çšããããšãå¯èœã§ãããæ¬åå¿ã¯æº¶åªäžçŽâ30
ã150â奜ãŸããã¯çŽïŒã100âã§è¡ããããäžè¬
åŒZY2ã§è¡šããããååç©ã¯ã¹ã«ãããŠã ããã²
ãã€ãïŒïŒã«å¯Ÿããéå°é䜿çšããŠãè¯ãã奜
ãŸããã¯çŽïŒãïŒåã¢ã«éã䜿çšããã溶åªã¯å
èšè£œé æ³ïŒ¡ã®åå¿ã«äœ¿çšå¯èœãªæº¶åªã䜿çšã§ã
ãã ã補é æ³ïŒ£ã äžè¬åŒïŒïŒã§è¡šããããã¹ã«ãããŠã ååç©
ã«é žåéãåå¿ãã äžè¬åŒ ïŒåŒäžR1ãR2ãïœåã³ïœã¯åèšãšåäžã®æå³ãæ
ãããïŒã§è¡šããããã¹ã«ãããŠã æ°Žé žåç©ãç
æããããããã«åé¢ããããšãªããHY2ïŒY2ã¯
åèšãšåäžã®æå³ãæãïŒã§è¡šããããååç©ãš
ãåå¿ãããããšã«ãããæ¬çºæååç©ïŒïŒã
åŸãã åæãšããŠçšããããã¹ã«ãããŠã ååç©
ïŒïŒã®å ·äœäŸãšããŠã¯ã補é æ³ïŒ¢ã§äŸç€ºããã
ã®ã䜿çšã§ãããåãHY2ã§è¡šããããååç©ãš
ããŠã¯ããšãŠåæ°ŽçŽ ãå¡©åæ°ŽçŽ ãèåæ°ŽçŽ ãç¡
é žããªã³é žãã¡ã¿ãªã³é žãé ¢é žãããããªã³é žã
ã€ãœé ªé žããã¬ã€ã³é žãããã³é žããããŒã«é žã
ã¯ãšã³é žãä¹³é žãé ç³é žãã¹ãã¢ãªã³é žããªããŒ
ã«é žããªã¬ã€ã³é žãã¢ã¹ã³ã«ãã³é žãã·ã¯ããã
ã·ã«ã¹ã«ãã¢ãã³é žãã¡ã¿ã³ã¹ã«ãã³é žããã³ãŒ
ã³ã¹ã«ãã³é žããã·ã«é žããã¯ãªã«ã¹ã«ãã³é žã
å®æ¯éŠé žããã³ãã³é žãã°ãªãã«ã¬ã·ã³é žãã°ãª
ãã«ãªãã³çã䜿çšãããã é žåéã®äœ¿çšå²åã¯ïŒïŒã®ã¹ã«ãããŠã åå
ç©ã«å¯ŸããŠçã¢ã«ä»¥äžã§ããã°ããã奜ãŸããã¯
çŽïŒãïŒã¢ã«æ¯ã§ãããHY2ã§è¡šããããååç©
ã®äœ¿çšå²åã¯ïŒïŒã®ã¹ã«ãããŠã ååç©ã«å¯Ÿã
ãŠçã¢ã«ä»¥äžã§ããã°è¯ãã奜ãŸããã¯çŽïŒãïŒ
ã¢ã«æ¯ã§ãããåå¿æº¶åªãšããŠã¯ãåèšè£œé æ³ïŒ¡
ã®åå¿ã«äœ¿çšå¯èœãªæº¶åªã䜿çšã§ãããåãåå¿
枩床ã¯éåžžçŽâ30ã150âã奜ãŸããã¯çŽïŒã100
âã§è¡ãªããããæ¬çºæã®ã¹ã«ãããŠã ååç©ã¯
éåžžã®åé¢æ¹æ³ãäŸãã°åçµæ¶ãã«ã©ã ã¯ããã
ã°ã©ãã€ãŒçã«ãã容æã«åé¢ã§ããã æ¬çºæã®ã¹ã«ãããŠã ååç©ã¯çäœã®å ç«èœã
亢é²ãåãå¶çäœçšãæããã®ã¿ãªãããå ç«èª¿
ç¯äœçšïŒæãªãŠããäœçšïŒæ¶çé®çäœçšïŒèæ©èœ
æ¹åäœçšïŒæèªå·±å ç«äœçšïŒæã¢ã¬ã«ã®ãŒäœçšïŒ
æåæ¯äœçšïŒææé²åŸ¡äœçšïŒã¹ããã€ãå€ãå¶ç
å€çã®å¯äœçšãšããŠå ç«æå¶äœçšãæããååç©
ã®å¯äœçšé²æ¢äœçšïŒå ç«çæ³ã®è£å©äœçšïŒè¡å°æ¿
åéé»æ¢äœçšïŒçç©æé·èª¿ç¯äœçšçãæãå»è¬
åã蟲è¬ãšããŠæçšã§ããã æ¬çºæååç©ã®å»è¬ãšããŠã®æäžåœ¢æ ãšããŠã¯
æ²»çç®çã«å¿ããŠåçš®ã®åœ¢æ ãæ¡çšå¯èœã§äŸãã°
çµå£å€ã泚å°å€ãçŽè žåå€çã®ãããã§ãããã
åœæ¥è ã«å ¬ç¥æ £çšã®è£œå€æ¹æ³ã«ãã補é ã§ããã
çµå£çšåºå補å€ã調補ããå Žåã¯æ¬çºæååç©ã«
賊圢å€ãæŽã«å¿ èŠã«å¿ããŠãçµåå€ã厩解å€ãæ»
æ²¢å€ãçè²å€ãç¯å³å€ãç¯èå€çãå ããåŸãåžž
æ³ã«ãããé å€ã被èŠé å€ãé¡ç²å€ãæ£å€ãã«ã
ã»ã«å€çãäœæããããšãã§ããã çµå£æ¶²ç¶è£œå€ã調補ããå Žåã«ã¯ãæ¬çºæåå
ç©ã«ç¯å³å€ãç·©è¡å€ãå®å®åå€ãç¯èå€çãå ã
ãŠãåžžæ³ã«ããå æ液å€ãã·ãããå€ããã©ã€ã·
ãããå€çã補é ããããšãã§ããã泚å°å€ã調
補ããå Žåã¯æ¬çºæååç©ã«PH調æŽå€ãç·©è¡å€ã
å®å®åå€ãç匵åå€ãå±æ麻é å€çãæ·»å ããåžž
æ³ã«ãããç®äžãçèå ãéèå çšæ³šå°å€ã補é
ããããšãã§ãããçŽè žåè¬è£œå€ã調補ããå Žå
ã«ã¯æ¬çºæååç©ã«è³Šåœ¢å€ãæŽã«å¿ èŠã«å¿ããŠç
é¢æŽ»æ§å€çãå ããåŸåžžæ³ã«ããåå€ã補é ãã
ããšãã§ããã äžèšã®æäžåäœåœ¢æ äžã«é åãããã¹ããã¹ã«
ãããŠã ååç©ã®éã¯çç¶ã«ãããæãã¯å€åã«
ããäžå®ã§ãªãããäžè¬ã«çµå£å€ã§ã¯çŽïŒã1000
mgã泚å°å€ã§ã¯çŽ0.5ã500mgãåå€ã§ã¯çŽïŒã
1000mgãšããã®ãæãŸãããåïŒæ¥åœãã®æäžé
ãçç¶çã«å¿ãäžæŠã«ã¯æ±ºå®ã§ããªããéåžžçŽ
0.5ã5000mgãšããã®ã奜ãŸããã 次ã«æ¬çºæã«ãããŠåŸãããååç©ãè¡šïŒã«ç€º
ãã â» è¡šïŒäž TsOïŒPsãGLã¯ä»¥äžã®ã¢ããªã³ã瀺ãã TsOïŒïœâãã«ãšã³ã¹ã«ãã³é žã®ã¢ããªã³ PsïŒãã¯ãªã«ã¹ã«ãã³é žã®ã¢ããªã³ GLïŒã°ãªãã«ãªãã³ã®ã¢ããªã³ ãŸãNMRã¯DMSOâd6äžãTMSãå éšæšæºç©
質ãšããŠæž¬å®ããã
ãè¡šã
ãè¡šã
ãè¡šã
ãè¡šã
ãè¡šã
ãè¡šã
ãè¡šã
ãè¡šã
ãè¡šã
ãè¡šã
ãè¡šã
ãè¡šã
ãè¡šã
ãè¡šã
ãè¡šã
ãè¡šã
次ã«æ¬çºæã®åèäŸåã³å®æœäŸãæããã
åèäŸ ïŒ
ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã¡
ãã«ã¹ã«ãã¢ã€ãã®åæ 18ïŒ æ°Žé žåãããªãŠã 氎溶液100mlã«ã¡ãã«ã¡
ã«ã«ãã¿ã³50ïœãå ãããã¡ãã¬ã³ïŒããã©ãã€
ããâïŒâãã©ãã«ïŒã¯ãã©ã€ã50ïœãå ããŠïŒ
æééæµããå·åŸãåå¿æ¶²ãã¡ãã¬ã³ã¯ãã©ã€ã
æœåºããååããã¡ãã¬ã³ã¯ãã©ã€ãå±€ãæ°ŽæŽ
ããç¡æ°Žç¡«é žãããªãŠã ã§ä¹Ÿç¥ããã也ç¥åŸèžç
ããã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒ
ã¡ãã«ã¹ã«ãã¢ã€ã37.5ïœïŒåç69.1ïŒ ïŒãåŸ
ãã bp 69ã70âïŒ10mmHg åèäŸ ïŒ ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã¡
ãã«ã¹ã«ãã¢ã€ãã®åæ ã¡ã¿ããŒã«350mlã«éå±ãããªãŠã 14ïœãå ã
ãŠæº¶è§£ããã¡ãã«ã¡ã«ã«ãã¿ã³63ïœæ¬¡ã«ãšãã¬ã³
ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã¯ãã©ã€ã75
ïœãå ããïŒæééæµããããå·åŸãéãã
液ãèžçãããšãã¬ã³ïŒããã©ãã€ããâïŒâã
ã©ãã«ïŒã¡ãã«ã¹ã«ãã¢ã€ã76.6ïœïŒåç93.7
ïŒ ïŒãåŸããbp113âïŒ33mmHg å®æœäŸ ïŒ ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ã¡ãã«ã¹ã«ãããŠã ãã·ã¬ãŒãïŒååç©50ïŒã®
åæ ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã¡
ãã«ã¹ã«ãã¢ã€ã15ïœããã·ã«é žã¡ãã«38ïœããš
ãŒãã«70mläžã«å ããŠã宀枩ã§ïŒæéåå¿ãã
ããäžæº¶ç©ãåããã¢ã»ããããªã«âãšãŒãã«
ããåçµæ¶ããã¡ãã¬ã³ïŒããã©ãã€ããâïŒâ
ãã©ãã«ïŒãžã¡ãã«ã¹ã«ãããŠã ãã·ã¬ãŒã32.1
ïœïŒåç93.9ïŒ ïŒãåŸãã m.p97ã98â å çŽ åæ C15H24O4S2ãšã㊠  èšç®å€ïŒïŒ ïŒ 54.19 7.28 å®æž¬å€ïŒïŒ ïŒ 54.16 7.39 å®æœäŸ ïŒ ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ã¡ãã«ã¹ã«ãããŠã ãã·ã¬ãŒãïŒååç©29ïŒã®
åæ ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã¡
ãã«ã¹ã«ãã¢ã€ã10.2ïœãšãã·ã«é žã¡ãã«19ïœã
宀枩ã§ïŒæéåå¿ãããããšãŒãã«ãå ããŠäžæº¶
éšãåããã¡ãã¬ã³ã¯ãã©ã€ãâãšãŒãã«ãã
åçµæ¶ãããšãã¬ã³ïŒããã©ãã€ããâïŒâãã©
ãã«ïŒãžã¡ãã«ã¹ã«ãããŠã ãã·ã¬ãŒã22.1ïœ
ïŒåç94.9ïŒ ïŒãåŸã m.p131.5ã132â å çŽ åæ C15H24O4S2ãšã㊠  èšç®å€ïŒïŒ ïŒ 54.19 7.28 å®æž¬å€ïŒïŒ ïŒ 54.25 7.54 å®æœäŸ ïŒ å®æœäŸïŒãšåæ§ã®æäœã«ããååç©ïŒã12ã
19ã21ã23ã42ã44ã46ã58ã63ãåæããã å®æœäŸ ïŒ ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ãšãã«ã¹ã«ãããŠã ãã·ã¬ãŒãïŒååç©52ïŒã®
åæ ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãš
ãã«ã¹ã«ãã¢ã€ã3.2ïœã®ã¡ãã¬ã³ã¯ãã©ã€ã30
ml溶液äžã«ããšãã«ã¢ã€ãªãã€ã6.0ïœæ¬¡ã«ãã·
ã«é žé5.6ïœãå ããŠã宀枩ã§ïŒæéåå¿ãã
ããåå¿åŸãéãã液ã«ç¡«åæ°ŽçŽ ã掻æ§çã
å ããŠéããã液ãæ¿çž®ããæ®æž£ãã¡ãã¬ã³
ã¯ãã©ã€ããšãŒãã«ã§ç²Ÿè£œããã¡ãã¬ã³ïŒããã©
ãã€ããâïŒâãã©ãã«ïŒãžãšãã«ã¹ã«ãããŠã
ãã·ã¬ãŒã6.3ïœïŒåç93.8ïŒ ïŒãåŸãã NMRïŒDMSOâd6 ppm
ãã«ã¹ã«ãã¢ã€ãã®åæ 18ïŒ æ°Žé žåãããªãŠã 氎溶液100mlã«ã¡ãã«ã¡
ã«ã«ãã¿ã³50ïœãå ãããã¡ãã¬ã³ïŒããã©ãã€
ããâïŒâãã©ãã«ïŒã¯ãã©ã€ã50ïœãå ããŠïŒ
æééæµããå·åŸãåå¿æ¶²ãã¡ãã¬ã³ã¯ãã©ã€ã
æœåºããååããã¡ãã¬ã³ã¯ãã©ã€ãå±€ãæ°ŽæŽ
ããç¡æ°Žç¡«é žãããªãŠã ã§ä¹Ÿç¥ããã也ç¥åŸèžç
ããã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒ
ã¡ãã«ã¹ã«ãã¢ã€ã37.5ïœïŒåç69.1ïŒ ïŒãåŸ
ãã bp 69ã70âïŒ10mmHg åèäŸ ïŒ ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã¡
ãã«ã¹ã«ãã¢ã€ãã®åæ ã¡ã¿ããŒã«350mlã«éå±ãããªãŠã 14ïœãå ã
ãŠæº¶è§£ããã¡ãã«ã¡ã«ã«ãã¿ã³63ïœæ¬¡ã«ãšãã¬ã³
ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã¯ãã©ã€ã75
ïœãå ããïŒæééæµããããå·åŸãéãã
液ãèžçãããšãã¬ã³ïŒããã©ãã€ããâïŒâã
ã©ãã«ïŒã¡ãã«ã¹ã«ãã¢ã€ã76.6ïœïŒåç93.7
ïŒ ïŒãåŸããbp113âïŒ33mmHg å®æœäŸ ïŒ ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ã¡ãã«ã¹ã«ãããŠã ãã·ã¬ãŒãïŒååç©50ïŒã®
åæ ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã¡
ãã«ã¹ã«ãã¢ã€ã15ïœããã·ã«é žã¡ãã«38ïœããš
ãŒãã«70mläžã«å ããŠã宀枩ã§ïŒæéåå¿ãã
ããäžæº¶ç©ãåããã¢ã»ããããªã«âãšãŒãã«
ããåçµæ¶ããã¡ãã¬ã³ïŒããã©ãã€ããâïŒâ
ãã©ãã«ïŒãžã¡ãã«ã¹ã«ãããŠã ãã·ã¬ãŒã32.1
ïœïŒåç93.9ïŒ ïŒãåŸãã m.p97ã98â å çŽ åæ C15H24O4S2ãšã㊠  èšç®å€ïŒïŒ ïŒ 54.19 7.28 å®æž¬å€ïŒïŒ ïŒ 54.16 7.39 å®æœäŸ ïŒ ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ã¡ãã«ã¹ã«ãããŠã ãã·ã¬ãŒãïŒååç©29ïŒã®
åæ ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã¡
ãã«ã¹ã«ãã¢ã€ã10.2ïœãšãã·ã«é žã¡ãã«19ïœã
宀枩ã§ïŒæéåå¿ãããããšãŒãã«ãå ããŠäžæº¶
éšãåããã¡ãã¬ã³ã¯ãã©ã€ãâãšãŒãã«ãã
åçµæ¶ãããšãã¬ã³ïŒããã©ãã€ããâïŒâãã©
ãã«ïŒãžã¡ãã«ã¹ã«ãããŠã ãã·ã¬ãŒã22.1ïœ
ïŒåç94.9ïŒ ïŒãåŸã m.p131.5ã132â å çŽ åæ C15H24O4S2ãšã㊠  èšç®å€ïŒïŒ ïŒ 54.19 7.28 å®æž¬å€ïŒïŒ ïŒ 54.25 7.54 å®æœäŸ ïŒ å®æœäŸïŒãšåæ§ã®æäœã«ããååç©ïŒã12ã
19ã21ã23ã42ã44ã46ã58ã63ãåæããã å®æœäŸ ïŒ ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ãšãã«ã¹ã«ãããŠã ãã·ã¬ãŒãïŒååç©52ïŒã®
åæ ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãš
ãã«ã¹ã«ãã¢ã€ã3.2ïœã®ã¡ãã¬ã³ã¯ãã©ã€ã30
ml溶液äžã«ããšãã«ã¢ã€ãªãã€ã6.0ïœæ¬¡ã«ãã·
ã«é žé5.6ïœãå ããŠã宀枩ã§ïŒæéåå¿ãã
ããåå¿åŸãéãã液ã«ç¡«åæ°ŽçŽ ã掻æ§çã
å ããŠéããã液ãæ¿çž®ããæ®æž£ãã¡ãã¬ã³
ã¯ãã©ã€ããšãŒãã«ã§ç²Ÿè£œããã¡ãã¬ã³ïŒããã©
ãã€ããâïŒâãã©ãã«ïŒãžãšãã«ã¹ã«ãããŠã
ãã·ã¬ãŒã6.3ïœïŒåç93.8ïŒ ïŒãåŸãã NMRïŒDMSOâd6 ppm
ãåŒã
ÎŽ3.77ïŒ2H
ãåŒãïŒ
ÎŽ3.43ïŒ2H
ãåŒãïŒ
ÎŽ3.35ïŒ4H
ãåŒãïŒ
å®æœäŸ ïŒ
å®æœäŸïŒãšåæ§ã®æäœã«ããååç©17ã18ã
25ã27ã40ã41ã45ã48ã54ã56ã59ã61ãåæ
ããã å®æœäŸ ïŒ ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ã¡ãã«ã¹ã«ãããŠã ãã¯ãªã«ã¹ã«ãããŒãïŒå
åç©ïŒïŒã®åæ ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ã¡ãã«ã¹ã«ãããŠã ãã·ã¬ãŒã9.5ïœãæ°Žã«æº¶è§£
ãããã¯ãªã«ã¹ã«ãã³é žãããªãŠã 12.6ïœãå ã
ããæåºçµæ¶ããšã¿ããŒã«ããåçµæ¶ããŠãã¡ã
ã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãžã¡ãã«
ã¹ã«ãããŠã ãã¯ãªã«ã¹ã«ãããŒã12.5ïœïŒåç
95ïŒ ïŒãåŸããmp205ã206â å çŽ åæ C13H17N3O10S2ãšã㊠   èšç®å€ïŒïŒ ïŒ 35.53 3.90 9.56 å®æž¬å€ïŒïŒ ïŒ 35.46 3.94 9.45 å®æœäŸ ïŒ å®æœäŸïŒãšåæ§ã®æäœã«ããååç©13ã15ã
20ã22ã24ã26ã28ã39ã43ã49ã53ã55ã57ã
60ã62ãåæããã å®æœäŸ ïŒ ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ã¡ãã«ã¹ã«ãããŠã ã¢ã€ãªãã€ãïŒååç©ïŒïŒ
ã®åæ ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã¡
ãã«ã¹ã«ãã¢ã€ã13.2ïœããšãŠåã¡ãã«30ïœã®æ··
液ã宀枩ã§ïŒæéåå¿ãããããšãŒãã«ãå ããŠ
äžæº¶ç©ãåãããäžæº¶ç©ãã¢ã»ããããªã«âãš
ãŒãã«ã§ç²Ÿè£œããã¡ãã¬ã³ïŒããã©ãã€ããâïŒ
âãã©ãã«ïŒãžã¡ãã«ã¹ã«ãããŠã ã¢ã€ãªãã€ã
26ïœïŒåç95.6ïŒ ïŒãåŸãã NMRïŒDMSâd6 ppmïŒ
25ã27ã40ã41ã45ã48ã54ã56ã59ã61ãåæ
ããã å®æœäŸ ïŒ ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ã¡ãã«ã¹ã«ãããŠã ãã¯ãªã«ã¹ã«ãããŒãïŒå
åç©ïŒïŒã®åæ ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ã¡ãã«ã¹ã«ãããŠã ãã·ã¬ãŒã9.5ïœãæ°Žã«æº¶è§£
ãããã¯ãªã«ã¹ã«ãã³é žãããªãŠã 12.6ïœãå ã
ããæåºçµæ¶ããšã¿ããŒã«ããåçµæ¶ããŠãã¡ã
ã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãžã¡ãã«
ã¹ã«ãããŠã ãã¯ãªã«ã¹ã«ãããŒã12.5ïœïŒåç
95ïŒ ïŒãåŸããmp205ã206â å çŽ åæ C13H17N3O10S2ãšã㊠   èšç®å€ïŒïŒ ïŒ 35.53 3.90 9.56 å®æž¬å€ïŒïŒ ïŒ 35.46 3.94 9.45 å®æœäŸ ïŒ å®æœäŸïŒãšåæ§ã®æäœã«ããååç©13ã15ã
20ã22ã24ã26ã28ã39ã43ã49ã53ã55ã57ã
60ã62ãåæããã å®æœäŸ ïŒ ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ã¡ãã«ã¹ã«ãããŠã ã¢ã€ãªãã€ãïŒååç©ïŒïŒ
ã®åæ ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã¡
ãã«ã¹ã«ãã¢ã€ã13.2ïœããšãŠåã¡ãã«30ïœã®æ··
液ã宀枩ã§ïŒæéåå¿ãããããšãŒãã«ãå ããŠ
äžæº¶ç©ãåãããäžæº¶ç©ãã¢ã»ããããªã«âãš
ãŒãã«ã§ç²Ÿè£œããã¡ãã¬ã³ïŒããã©ãã€ããâïŒ
âãã©ãã«ïŒãžã¡ãã«ã¹ã«ãããŠã ã¢ã€ãªãã€ã
26ïœïŒåç95.6ïŒ ïŒãåŸãã NMRïŒDMSâd6 ppmïŒ
ãåŒã
ÎŽ4.20ïŒ1H
ãåŒãïŒÎŽ3.42ïŒ2H
ãåŒãïŒÎŽ2.86ïŒ6H
ãåŒãïŒ
å®æœäŸ ïŒ
å®æœäŸïŒãšåæ§ã®æäœã«ããååç©16ã30ã31
ãåæããã å®æœäŸ 10 ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ã¡ãã«ã¹ã«ãããŠã ã·ã¯ãããã·ã«ã¹ã«ãã¢ã¡
ãŒãïŒååç©ïŒïŒã®åæ ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ã¡ãã«ã¹ã«ãããŠã ã¢ã€ãªãã€ã13.7ïœãã·ã¯ã
ããã·ã«ã¹ã«ãã¢ãã³é žé15.7ïœããšã¿ããŒã«
200mläžã«å ããŠå®€æž©ã§ïŒæéåå¿ããããåå¿
åŸãéãã液ã«ç¡«åæ°ŽçŽ ãå ããåŸã掻æ§ç
åŠçãããéåŸã液ãæ¿çž®ããæ®æž£ããšã¿ã
ãŒã«âãšãŒãã«ããåçµæ¶ããã¡ãã¬ã³ïŒããã©
ãã€ããâïŒâãã©ãã«ïŒãžã¡ãã«ã¹ã«ãããŠã
ã·ã¯ãããã·ã«ã¹ã«ãã¢ã¡ãŒã15.4ïœïŒåç90.5
ïŒ ïŒãåŸããmp63ã64â å çŽ åæ C13H27NO4S29/10H2Oãšã㊠   èšç®å€ïŒïŒ ïŒ 45.70 8.50 4.10 å®æž¬å€ïŒïŒ ïŒ 45.69 8.78 4.29 å®æœäŸ 11 å®æœäŸïŒãšåæ§ã®æäœã«ããååç©ïŒã10ã32
ã36ã47ã51ãåæããã å®æœäŸ 12 ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ã¡ãã«ã¹ã«ãããŠã ã·ã¯ãããã·ã«ã¹ã«ãã¢ã¡
ãŒãïŒååç©37ïŒã®åæ ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ã¡ãã«ã¹ã«ãããŠã ã¯ãã©ã€ã9.8ïœãã·ã¯ãã
ãã·ã«ã¹ã«ãã¢ãã³é žé17ïœãã¢ã»ããããªã«60
mläžã«å ããŠã宀枩ã§ïŒæéåå¿ãããã以äžå®
æœäŸ10ãšåæ§ã«åŠçãããšãã¬ã³ïŒããã©ãã€ã
ãâïŒâãã©ãã«ïŒãžã¡ãã«ã¹ã«ãããŠã ã·ã¯ã
ããã·ã«ã¹ã«ãã¢ã¡ãŒã15.6ïœïŒåç92ïŒ ïŒãåŸ
ããmp69ã70â å çŽ åæ C14H29NO4S27/6H2Oãšã㊠   èšç®å€ïŒïŒ ïŒ 46.79 8.75 3.90 å®æž¬å€ïŒïŒ ïŒ 46.65 8.86 4.20 å®æœäŸ 13 ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã¡
ãã«âïœâãã·ã«ã¹ã«ãããŠã ãã·ã¬ãŒãïŒå
åç©14ïŒã®åæ ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã¡
ãã«âïœâãã·ã«ã¹ã«ãããŠã ã¢ã€ãªãã€ã18.3
ïœãã¢ã»ããããªã«150mlã«æº¶è§£ãããã·ã«é žé
13ïœãå ããŠå®€æž©ã§ïŒæéæ¹æãããæ²æ®¿ç©ã
å»ãã液ã«ç¡«åæ°ŽçŽ ãå ãæ²æ®¿ç©ãå»ããã
液ãæ¿çž®ããæ®æž£ãã¡ãã¬ã³ã¯ãã©ã€ãâãšãŒ
ãã«ãã粟補ããã¡ãã¬ã³ïŒããã©ãã€ããâïŒ
âãã©ãã«ïŒã¡ãã«âïœâãã·ã«ã¹ã«ãããŠã ã
ã·ã¬ãŒã18.6ïœïŒåç91.6ïŒ ïŒãåŸãã NMRïŒDMSOâd6 ppmïŒ ÎŽ3.71ïŒ2H
ãåæããã å®æœäŸ 10 ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ã¡ãã«ã¹ã«ãããŠã ã·ã¯ãããã·ã«ã¹ã«ãã¢ã¡
ãŒãïŒååç©ïŒïŒã®åæ ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ã¡ãã«ã¹ã«ãããŠã ã¢ã€ãªãã€ã13.7ïœãã·ã¯ã
ããã·ã«ã¹ã«ãã¢ãã³é žé15.7ïœããšã¿ããŒã«
200mläžã«å ããŠå®€æž©ã§ïŒæéåå¿ããããåå¿
åŸãéãã液ã«ç¡«åæ°ŽçŽ ãå ããåŸã掻æ§ç
åŠçãããéåŸã液ãæ¿çž®ããæ®æž£ããšã¿ã
ãŒã«âãšãŒãã«ããåçµæ¶ããã¡ãã¬ã³ïŒããã©
ãã€ããâïŒâãã©ãã«ïŒãžã¡ãã«ã¹ã«ãããŠã
ã·ã¯ãããã·ã«ã¹ã«ãã¢ã¡ãŒã15.4ïœïŒåç90.5
ïŒ ïŒãåŸããmp63ã64â å çŽ åæ C13H27NO4S29/10H2Oãšã㊠   èšç®å€ïŒïŒ ïŒ 45.70 8.50 4.10 å®æž¬å€ïŒïŒ ïŒ 45.69 8.78 4.29 å®æœäŸ 11 å®æœäŸïŒãšåæ§ã®æäœã«ããååç©ïŒã10ã32
ã36ã47ã51ãåæããã å®æœäŸ 12 ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ã¡ãã«ã¹ã«ãããŠã ã·ã¯ãããã·ã«ã¹ã«ãã¢ã¡
ãŒãïŒååç©37ïŒã®åæ ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ã¡ãã«ã¹ã«ãããŠã ã¯ãã©ã€ã9.8ïœãã·ã¯ãã
ãã·ã«ã¹ã«ãã¢ãã³é žé17ïœãã¢ã»ããããªã«60
mläžã«å ããŠã宀枩ã§ïŒæéåå¿ãããã以äžå®
æœäŸ10ãšåæ§ã«åŠçãããšãã¬ã³ïŒããã©ãã€ã
ãâïŒâãã©ãã«ïŒãžã¡ãã«ã¹ã«ãããŠã ã·ã¯ã
ããã·ã«ã¹ã«ãã¢ã¡ãŒã15.6ïœïŒåç92ïŒ ïŒãåŸ
ããmp69ã70â å çŽ åæ C14H29NO4S27/6H2Oãšã㊠   èšç®å€ïŒïŒ ïŒ 46.79 8.75 3.90 å®æž¬å€ïŒïŒ ïŒ 46.65 8.86 4.20 å®æœäŸ 13 ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã¡
ãã«âïœâãã·ã«ã¹ã«ãããŠã ãã·ã¬ãŒãïŒå
åç©14ïŒã®åæ ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒã¡
ãã«âïœâãã·ã«ã¹ã«ãããŠã ã¢ã€ãªãã€ã18.3
ïœãã¢ã»ããããªã«150mlã«æº¶è§£ãããã·ã«é žé
13ïœãå ããŠå®€æž©ã§ïŒæéæ¹æãããæ²æ®¿ç©ã
å»ãã液ã«ç¡«åæ°ŽçŽ ãå ãæ²æ®¿ç©ãå»ããã
液ãæ¿çž®ããæ®æž£ãã¡ãã¬ã³ã¯ãã©ã€ãâãšãŒ
ãã«ãã粟補ããã¡ãã¬ã³ïŒããã©ãã€ããâïŒ
âãã©ãã«ïŒã¡ãã«âïœâãã·ã«ã¹ã«ãããŠã ã
ã·ã¬ãŒã18.6ïœïŒåç91.6ïŒ ïŒãåŸãã NMRïŒDMSOâd6 ppmïŒ ÎŽ3.71ïŒ2H
ãåŒãïŒ
ÎŽ3.10ã3.60ïŒ4H
ãåŒãïŒ
ÎŽ2.89ïŒ3H
ãåŒãïŒ
å®æœäŸ 14
ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ã¡ãã«ã¹ã«ãããŠã ã°ãªãã«ãªããšãŒãïŒåå
ç©38ïŒã®åæ ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ã¡ãã«ã¹ã«ãããŠã ã¢ã€ãªãã€ã13.7ïœãã¡ã¿ã
ãŒã«400mlã«æº¶è§£ããé žåé41.2ïœå ããŠã宀枩
ã§ïŒæéåå¿åŸãéããã液ã«ã°ãªãã«ããª
ã³41.2ïœã®ã¡ã¿ããŒã«300mlãå ããåŸãæ¿çž®ã
åŸãããæ®æž£ãã¯ãããã«ã âãšãŒãã«ããåçµ
æ¶ãããšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãžã¡ãã«ã¹ã«ãããŠã ã°ãªãã«ãªããšãŒã42
ïœïŒåç89.9ïŒ ïŒãåŸãã mp202ã203â å çŽ åæ C50H78O17Sãšã㊠  èšç®å€ïŒïŒ ïŒ 61.08 7.10 枬å®å€ïŒïŒ ïŒ 61.29 7.20 å®æœäŸ 15 ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ã¡ãã«ã¹ã«ãããŠã ã©ã¯ããŒãïŒååç©ïŒïŒã®
åæ ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ã¡ãã«ã¹ã«ãããŠã ã¢ã€ãªãã€ã26ïœãã¡ã¿ããŒ
ã«400mlã«æº¶è§£ããé žåé23ïœãå ããŠå®€æž©ã§ïŒ
æéåå¿åŸéããã液ã«ä¹³é ž10ïœã溶解ãã
ã¡ã¿ããŒã«æº¶æ¶²50mlãå ããåŸãæ¿çž®ããåŸãã
ãæ®æž£ãã¡ã¿ããŒã«âãšãŒãã«ã§ç²Ÿè£œããã¡ãã¬
ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãžã¡ãã«ã¹
ã«ãããŠã ã©ã¯ããŒã20ïœïŒåç89.3ïŒ ïŒãåŸ
ãã NMRïŒDMSOâd6 ppmïŒ ÎŽ3.73ïŒ2H
ã¡ãã«ã¹ã«ãããŠã ã°ãªãã«ãªããšãŒãïŒåå
ç©38ïŒã®åæ ãšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ã¡ãã«ã¹ã«ãããŠã ã¢ã€ãªãã€ã13.7ïœãã¡ã¿ã
ãŒã«400mlã«æº¶è§£ããé žåé41.2ïœå ããŠã宀枩
ã§ïŒæéåå¿åŸãéããã液ã«ã°ãªãã«ããª
ã³41.2ïœã®ã¡ã¿ããŒã«300mlãå ããåŸãæ¿çž®ã
åŸãããæ®æž£ãã¯ãããã«ã âãšãŒãã«ããåçµ
æ¶ãããšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãžã¡ãã«ã¹ã«ãããŠã ã°ãªãã«ãªããšãŒã42
ïœïŒåç89.9ïŒ ïŒãåŸãã mp202ã203â å çŽ åæ C50H78O17Sãšã㊠  èšç®å€ïŒïŒ ïŒ 61.08 7.10 枬å®å€ïŒïŒ ïŒ 61.29 7.20 å®æœäŸ 15 ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ã¡ãã«ã¹ã«ãããŠã ã©ã¯ããŒãïŒååç©ïŒïŒã®
åæ ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ã¡ãã«ã¹ã«ãããŠã ã¢ã€ãªãã€ã26ïœãã¡ã¿ããŒ
ã«400mlã«æº¶è§£ããé žåé23ïœãå ããŠå®€æž©ã§ïŒ
æéåå¿åŸéããã液ã«ä¹³é ž10ïœã溶解ãã
ã¡ã¿ããŒã«æº¶æ¶²50mlãå ããåŸãæ¿çž®ããåŸãã
ãæ®æž£ãã¡ã¿ããŒã«âãšãŒãã«ã§ç²Ÿè£œããã¡ãã¬
ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãžã¡ãã«ã¹
ã«ãããŠã ã©ã¯ããŒã20ïœïŒåç89.3ïŒ ïŒãåŸ
ãã NMRïŒDMSOâd6 ppmïŒ ÎŽ3.73ïŒ2H
ãåŒãïŒ
ÎŽ3.53ïŒ2H
ãåŒãïŒ
ÎŽ2.94ïŒ6H
ãåŒãïŒ
ÎŽ1.08ïŒ3H
ãåŒãïŒ
å®æœäŸ 16
ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ã¡ãã«ã¹ã«ãããŠã ã°ãªãã«ãªããšãŒãïŒåå
ç©11ïŒã®åæ ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ã¡ãã«ã¹ã«ãããŠã ã¢ã€ãªãã€ã13ïœãã¡ã¿ããŒ
ã«800mlã«æº¶è§£ããé žåé41.2ïœãå ããŠå®€æž©ã§
ïŒæéåå¿åŸéããã液ã«ã°ãªãã«ãªãã³
41.2ïœã®ã¡ã¿ããŒã«æº¶æ¶²400mlãå ããåŸãæ¿çž®
ããåŸãããæ®æž£ãã¯ãããã«ã âãšãŒãã«ãã
åçµæ¶ããã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©
ãã«ïŒãžã¡ãã«ã¹ã«ãããŠã ã°ãªãã«ãªããšãŒã
40ïœïŒåç87.0ïŒ ïŒãåŸãã mp204ã205âïŒåè§£ïŒ å çŽ åæ C49H76O17Sãšã㊠  èšç®å€ïŒïŒ ïŒ 60.72 7.90 å®æž¬å€ïŒïŒ ïŒ 60.77 7.81 次ã«æ¬çºæååç©ã®è£œå€äŸã瀺ãã 補å€äŸ ïŒ é å€ ååç©46 ïŒmg çµæ¶ã»ã«ããŒã¹ 35mg ä¹³ ç³ 39mg ãšãããããã§ãã·ã 15mg ããããã·ãããã«ã»ã«ããŒã¹ ïŒmgã¹ãã¢ãªã³é žãã°ãã·ãŠã ïŒmg ïŒé åœã 100mg äžèšé åå²åã§é å€ã調補ããã 補å€äŸ ïŒ ã«ãã»ã«å€ ååç©29 250 mg çµæ¶ã»ã«ããŒã¹ 70 mg ä¹³ ç³ 23 mg çµè³ªç¡æ°Žã±ã€é ž 3.5mgã¹ãã¢ãªã³é žãã°ãã·ãŠã 3.5mg ïŒã«ãã»ã«åœã 350 mg äžèšé åå²åã§é å€ã調補ããã 補é äŸ ïŒ çŽ°ç²å€ ååç©ïŒ 500mg çµæ¶ã»ã«ããŒã¹ 40mg ä¹³ ç³ 200mg ãšãããããã§ãã·ã 200mg ããããã·ãããã«ã»ã«ããŒã¹ 50mgã¹ãã¢ãªã³é žãã°ãã·ãŠã 10mg ïŒå åœã 1000mg äžèšé åå²åã§çŽ°ç²å€ã調補ããã 補é äŸ ïŒ é¡ç²å€ ååç©58 500mg çµæ¶ã»ã«ããŒã¹ 40mg ãšãããããã§ãã·ã 100mg ä¹³ ç³ 300mg ããããã·ãããã«ã»ã«ããŒã¹ 50mgã¹ãã¢ãªã³é žãã°ãã·ãŠã 10mg äžå åœã 1000mg äžèšé åå²åã§é¡ç²å€ã調補ããã 補å€äŸ ïŒ ã·ãããå€ ååç©50 5.0ïœ çœ ç³ 32.5ïœ ãã©ããããã·å®æ¯éŠé žãšãã« ïŒ mg ãã©ããããã·å®æ¯éŠé žããã« ïŒ mg çè²å€ 埮é éŠ æ 埮é粟補氎 é©é å šé50 ml äžèšé åå²åã§ã·ãããå€ã調補ããã 補å€äŸ ïŒ å å€ ååç©29 0.5ïœãŠã€ããããŸãŒã«ïŒ·â35 1.5ïœ ïŒååœã 2.0ïœ äžèšé åå²åã§åå€ã調補ããã 補å€äŸ ïŒ æ³šå°å€ ååç©28 10mg å¡©åãããªãŠã ïŒmg泚å°çšèžçæ°Ž é©é å šéïŒml äžèšé åå²åã§æ³šå°å€ã調補ããã 次ã«æ¬çºæååç©ã®è¬çäœçšè©Šéšãæ¥æ§æ¯æ§è©Š
éšçµæãäŸç€ºããã (1) åç³»è «çã¡ã¹âïŒMethâïŒã«å¯Ÿããå¶
çå¹æ BALBïŒïŒ£ç³»éæ§ããŠã¹ïŒäœé25ã30ïœïŒïŒ
矀10å¹ã䜿çšããã¡ã¹â现èïŒÃ104åãç®
äžã«ç§»æ€ãããååç©ã¯ççé£å¡©æ°Žã«æº¶è§£ãã
è «ç移æ€ç¿æ¥ããïŒæ¥ïŒåé£ç¶ïŒæ¥ééèå æ
äžãããè «ç移æ€åŸ17æ¥ç®ã«è «çãæåºããã
ã®ééã枬å®ãããè «ç现èå¢æ®æå¶çãç®åº
ãè¡šïŒã«ç€ºãåç³»è «çã¡ã¹âã«å¯ŸããŠæå¶å¹
æãèªããããã
ã¡ãã«ã¹ã«ãããŠã ã°ãªãã«ãªããšãŒãïŒåå
ç©11ïŒã®åæ ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒãž
ã¡ãã«ã¹ã«ãããŠã ã¢ã€ãªãã€ã13ïœãã¡ã¿ããŒ
ã«800mlã«æº¶è§£ããé žåé41.2ïœãå ããŠå®€æž©ã§
ïŒæéåå¿åŸéããã液ã«ã°ãªãã«ãªãã³
41.2ïœã®ã¡ã¿ããŒã«æº¶æ¶²400mlãå ããåŸãæ¿çž®
ããåŸãããæ®æž£ãã¯ãããã«ã âãšãŒãã«ãã
åçµæ¶ããã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©
ãã«ïŒãžã¡ãã«ã¹ã«ãããŠã ã°ãªãã«ãªããšãŒã
40ïœïŒåç87.0ïŒ ïŒãåŸãã mp204ã205âïŒåè§£ïŒ å çŽ åæ C49H76O17Sãšã㊠  èšç®å€ïŒïŒ ïŒ 60.72 7.90 å®æž¬å€ïŒïŒ ïŒ 60.77 7.81 次ã«æ¬çºæååç©ã®è£œå€äŸã瀺ãã 補å€äŸ ïŒ é å€ ååç©46 ïŒmg çµæ¶ã»ã«ããŒã¹ 35mg ä¹³ ç³ 39mg ãšãããããã§ãã·ã 15mg ããããã·ãããã«ã»ã«ããŒã¹ ïŒmgã¹ãã¢ãªã³é žãã°ãã·ãŠã ïŒmg ïŒé åœã 100mg äžèšé åå²åã§é å€ã調補ããã 補å€äŸ ïŒ ã«ãã»ã«å€ ååç©29 250 mg çµæ¶ã»ã«ããŒã¹ 70 mg ä¹³ ç³ 23 mg çµè³ªç¡æ°Žã±ã€é ž 3.5mgã¹ãã¢ãªã³é žãã°ãã·ãŠã 3.5mg ïŒã«ãã»ã«åœã 350 mg äžèšé åå²åã§é å€ã調補ããã 補é äŸ ïŒ çŽ°ç²å€ ååç©ïŒ 500mg çµæ¶ã»ã«ããŒã¹ 40mg ä¹³ ç³ 200mg ãšãããããã§ãã·ã 200mg ããããã·ãããã«ã»ã«ããŒã¹ 50mgã¹ãã¢ãªã³é žãã°ãã·ãŠã 10mg ïŒå åœã 1000mg äžèšé åå²åã§çŽ°ç²å€ã調補ããã 補é äŸ ïŒ é¡ç²å€ ååç©58 500mg çµæ¶ã»ã«ããŒã¹ 40mg ãšãããããã§ãã·ã 100mg ä¹³ ç³ 300mg ããããã·ãããã«ã»ã«ããŒã¹ 50mgã¹ãã¢ãªã³é žãã°ãã·ãŠã 10mg äžå åœã 1000mg äžèšé åå²åã§é¡ç²å€ã調補ããã 補å€äŸ ïŒ ã·ãããå€ ååç©50 5.0ïœ çœ ç³ 32.5ïœ ãã©ããããã·å®æ¯éŠé žãšãã« ïŒ mg ãã©ããããã·å®æ¯éŠé žããã« ïŒ mg çè²å€ 埮é éŠ æ 埮é粟補氎 é©é å šé50 ml äžèšé åå²åã§ã·ãããå€ã調補ããã 補å€äŸ ïŒ å å€ ååç©29 0.5ïœãŠã€ããããŸãŒã«ïŒ·â35 1.5ïœ ïŒååœã 2.0ïœ äžèšé åå²åã§åå€ã調補ããã 補å€äŸ ïŒ æ³šå°å€ ååç©28 10mg å¡©åãããªãŠã ïŒmg泚å°çšèžçæ°Ž é©é å šéïŒml äžèšé åå²åã§æ³šå°å€ã調補ããã 次ã«æ¬çºæååç©ã®è¬çäœçšè©Šéšãæ¥æ§æ¯æ§è©Š
éšçµæãäŸç€ºããã (1) åç³»è «çã¡ã¹âïŒMethâïŒã«å¯Ÿããå¶
çå¹æ BALBïŒïŒ£ç³»éæ§ããŠã¹ïŒäœé25ã30ïœïŒïŒ
矀10å¹ã䜿çšããã¡ã¹â现èïŒÃ104åãç®
äžã«ç§»æ€ãããååç©ã¯ççé£å¡©æ°Žã«æº¶è§£ãã
è «ç移æ€ç¿æ¥ããïŒæ¥ïŒåé£ç¶ïŒæ¥ééèå æ
äžãããè «ç移æ€åŸ17æ¥ç®ã«è «çãæåºããã
ã®ééã枬å®ãããè «ç现èå¢æ®æå¶çãç®åº
ãè¡šïŒã«ç€ºãåç³»è «çã¡ã¹âã«å¯ŸããŠæå¶å¹
æãèªããããã
ãè¡šã
(2) å®éšç§»æ€çã¶ã«ã³ãŒã180ã«å¯Ÿããå¶çå¹æ
ICRç³»éæ§ããŠã¹ïŒäœé30ã35ïœïŒïŒçŸ€10å¹
ã䜿çšããã¶ã«ã³ãŒã180现èïŒÃ105åãç®äž
ã«ç§»æ€ãããååç©ã¯ççé£å¡©æ°Žã«æº¶è§£ããè «
ç移æ€ç¿æ¥ããïŒæ¥ïŒåé£ç¶10æ¥ééèå æäž
ãããè «ç移æ€åŸ17æ¥ç®ã«è «çãæåºãããã®
ééã枬å®ãããè «ç现èå¢æ®æå¶çãç®åº
ããè¡šïŒã«ç€ºããå®éšç§»æ€çã¶ã«ã³ãŒã180ã«
察ããŠæå¶å¹æãèªããããã
ã䜿çšããã¶ã«ã³ãŒã180现èïŒÃ105åãç®äž
ã«ç§»æ€ãããååç©ã¯ççé£å¡©æ°Žã«æº¶è§£ããè «
ç移æ€ç¿æ¥ããïŒæ¥ïŒåé£ç¶10æ¥ééèå æäž
ãããè «ç移æ€åŸ17æ¥ç®ã«è «çãæåºãããã®
ééã枬å®ãããè «ç现èå¢æ®æå¶çãç®åº
ããè¡šïŒã«ç€ºããå®éšç§»æ€çã¶ã«ã³ãŒã180ã«
察ããŠæå¶å¹æãèªããããã
ãè¡šã
ãè¡šã
(3) ïŒâã¡ãã«ã³ã©ã³ãã¬ã³èªçºå¯ç§»æ€æ§è
«çã«
察ããå¶çå¹æ â57BLïŒïŒç³»éæ§ããŠã¹ïŒäœé20ã25
ïœïŒïŒçŸ€10å¹ã䜿çšãããè «ç现èã¯ïŒ£â
57BLïŒïŒç³»éæ§ããŠã¹ã«ïŒâã¡ãã«ã³ã©ã³ã
ã¬ã³ãç®äžæäžããŠèªçºããè «çãåç³»ããŠã¹
ã«è ¹æ°Žåã§ç¶ä»£ããŠãããã®ã§ããããã®è «ç
现èïŒÃ104ååã¯ïŒÃ105åãããŠã¹ã®èéšã«
ç®äžç§»æ€ãããååç©ã¯ççé£å¡©æ°Žã«æº¶è§£ãã
è «ç移æ€åŸïŒãïŒãïŒãïŒãïŒæ¥ç®ã«éèå æ
äžãããè «ç移æ€21æ¥ç®ã«è «çãæåºãããã®
ééã枬å®ãããè «ç现èå¢æ®æå¶çãç®åº
ããè¡šïŒã«ç€ºããïŒâã¡ãã«ã³ã©ã³ãã¬ã³èªçº
å¯ç§»æ€æ§è «çã«å¯Ÿããæå¶å¹æãèªããããã
察ããå¶çå¹æ â57BLïŒïŒç³»éæ§ããŠã¹ïŒäœé20ã25
ïœïŒïŒçŸ€10å¹ã䜿çšãããè «ç现èã¯ïŒ£â
57BLïŒïŒç³»éæ§ããŠã¹ã«ïŒâã¡ãã«ã³ã©ã³ã
ã¬ã³ãç®äžæäžããŠèªçºããè «çãåç³»ããŠã¹
ã«è ¹æ°Žåã§ç¶ä»£ããŠãããã®ã§ããããã®è «ç
现èïŒÃ104ååã¯ïŒÃ105åãããŠã¹ã®èéšã«
ç®äžç§»æ€ãããååç©ã¯ççé£å¡©æ°Žã«æº¶è§£ãã
è «ç移æ€åŸïŒãïŒãïŒãïŒãïŒæ¥ç®ã«éèå æ
äžãããè «ç移æ€21æ¥ç®ã«è «çãæåºãããã®
ééã枬å®ãããè «ç现èå¢æ®æå¶çãç®åº
ããè¡šïŒã«ç€ºããïŒâã¡ãã«ã³ã©ã³ãã¬ã³èªçº
å¯ç§»æ€æ§è «çã«å¯Ÿããæå¶å¹æãèªããããã
ãè¡šã
ãè¡šã
(4) 液æ§æäœç£çã«å¯Ÿããå¹æ
BALBïŒïŒ£ç³»éæ§ããŠã¹ïŒäœé25ã30ïœïŒïŒ
矀10å¹ãçšããçŸèµ€è¡çãæåãšã107åãé
èå 泚å°ãããååç©ã¯ççé£å¡©æ°Žã«æº¶è§£ãã
çŸèµ€è¡çæäœåææ¥ããé£ç¶ïŒæ¥éè ¹è å æäž
ããã æäœåŸïŒæ¥ç®ã«ããŠã¹èŸçŽ°èäžã®æäœç£ç现
èæ°ãã€ãšã«ãã®æ¹æ³ïŒã€ãšã«ãïŒJerneãet
alïŒãµã€ãšã³ã¹ïŒScienceïŒ140ã405ïŒ1963ïŒ
ã«åºã¥ãã«ãã³ã¬ã ã®å€æ³ïŒã«ãã³ã¬ã
ïŒCunninghamãet alïŒã€ã ãããžãŒ
ïŒImmunologyïŒ14ã599ïŒ1968ïŒã«ããæ±ãã
çµæãè¡šïŒã«ç€ºãã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒ
ãžã¡ãã«ã¹ã«ãããŠã ãã·ã¬ãŒãïŒååç©ïŒïŒ
ã§ã¯2.5mgã40mgæäžã§æ¶²æ§æäœç£ç现èæ°ã®
ææãªäžæãèªããããã
矀10å¹ãçšããçŸèµ€è¡çãæåãšã107åãé
èå 泚å°ãããååç©ã¯ççé£å¡©æ°Žã«æº¶è§£ãã
çŸèµ€è¡çæäœåææ¥ããé£ç¶ïŒæ¥éè ¹è å æäž
ããã æäœåŸïŒæ¥ç®ã«ããŠã¹èŸçŽ°èäžã®æäœç£ç现
èæ°ãã€ãšã«ãã®æ¹æ³ïŒã€ãšã«ãïŒJerneãet
alïŒãµã€ãšã³ã¹ïŒScienceïŒ140ã405ïŒ1963ïŒ
ã«åºã¥ãã«ãã³ã¬ã ã®å€æ³ïŒã«ãã³ã¬ã
ïŒCunninghamãet alïŒã€ã ãããžãŒ
ïŒImmunologyïŒ14ã599ïŒ1968ïŒã«ããæ±ãã
çµæãè¡šïŒã«ç€ºãã ã¡ãã¬ã³ïŒããã©ãã€ããâïŒâãã©ãã«ïŒ
ãžã¡ãã«ã¹ã«ãããŠã ãã·ã¬ãŒãïŒååç©ïŒïŒ
ã§ã¯2.5mgã40mgæäžã§æ¶²æ§æäœç£ç现èæ°ã®
ææãªäžæãèªããããã
ãè¡šã
(5) 现èæ§å
ç«ã«å¯Ÿããå¹æ
C57BLïŒïŒç³»éæ§ããŠã¹ïŒäœé20ã25ïœïŒ
ïŒçŸ€10å¹ã䜿çšãããå¡©åãã¯ãªã«ãæåãš
ãããšã¿ããŒã«ã«æº¶è§£ããïŒïŒ å¡©åãã¯ãªã«æº¶
液0.1mlãåæ¥åªæ¯ããããŠã¹ã®è ¹éšã«å¡åžã
ããïŒæ¥åŸã«ãªãªãŒã油溶解ããïŒïŒ å¡©åãã¯
ãªã«æº¶æ¶²ã®0.02mlãããŠã¹ã®äž¡è³ã«å¡åžãã24
æéåŸè³ã«ã¿ãããè «çããã€ã¢ã«ã·ãã¯ãã¹
ã²ãŒãžã§æž¬å®ãããæ€äœã¯å ç«ç¿æ¥ããé£ç¶ïŒ
æ¥éçµå£æäžããå¯Ÿç §çŸ€ã¯èžçæ°Žãæäžããã
çµæãè¡šïŒã«ç€ºããã¡ãã¬ã³ïŒããã©ãã€ãã
âïŒâãã©ãã«ïŒãžã¡ãã«ã¹ã«ãããŠã ãã·ã¬
ãŒãããšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãžã¡ãã«ã¹ã«ãããŠã ãã·ã¬ãŒãã«é 延å
éæåå¿ãå¢åŒ·ããäœçšã瀺ããã
ïŒçŸ€10å¹ã䜿çšãããå¡©åãã¯ãªã«ãæåãš
ãããšã¿ããŒã«ã«æº¶è§£ããïŒïŒ å¡©åãã¯ãªã«æº¶
液0.1mlãåæ¥åªæ¯ããããŠã¹ã®è ¹éšã«å¡åžã
ããïŒæ¥åŸã«ãªãªãŒã油溶解ããïŒïŒ å¡©åãã¯
ãªã«æº¶æ¶²ã®0.02mlãããŠã¹ã®äž¡è³ã«å¡åžãã24
æéåŸè³ã«ã¿ãããè «çããã€ã¢ã«ã·ãã¯ãã¹
ã²ãŒãžã§æž¬å®ãããæ€äœã¯å ç«ç¿æ¥ããé£ç¶ïŒ
æ¥éçµå£æäžããå¯Ÿç §çŸ€ã¯èžçæ°Žãæäžããã
çµæãè¡šïŒã«ç€ºããã¡ãã¬ã³ïŒããã©ãã€ãã
âïŒâãã©ãã«ïŒãžã¡ãã«ã¹ã«ãããŠã ãã·ã¬
ãŒãããšãã¬ã³ïŒããã©ãã€ããâïŒâãã©ã
ã«ïŒãžã¡ãã«ã¹ã«ãããŠã ãã·ã¬ãŒãã«é 延å
éæåå¿ãå¢åŒ·ããäœçšã瀺ããã
ãè¡šã
(6) æ¥æ§æ¯æ§è©Šéš
ddYéæ§ããŠã¹ïŒäœéçŽ20ïœïŒã䜿çšããå
åç©ãççé£å¡©æ°Žã«æº¶è§£ããéèå æäžã50ïŒ
èŽæ»éLD50ïŒmg/KgïŒãã¢ããããŠã³æ³ã«ãã
æ±ãããçµæãè¡šïŒã«ç€ºãã
åç©ãççé£å¡©æ°Žã«æº¶è§£ããéèå æäžã50ïŒ
èŽæ»éLD50ïŒmg/KgïŒãã¢ããããŠã³æ³ã«ãã
æ±ãããçµæãè¡šïŒã«ç€ºãã
ãè¡šã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ äžè¬åŒ ïŒåŒäžR1ãR2ã¯ã¢ã«ãã«ãã·ã¯ãã¢ã«ãã«ãã¢ã«
ã±ãã«ããã³ãŒã³ç°äžã«çœ®æåºãšããŠã¢ã«ãã«ã
ã¢ã«ã³ãã·åã¯ããã²ã³ãæããããšã®ããã¢ã©
ã«ãã«ã眮æåºãšããŠã¢ã«ãã«ãã¢ã«ã³ãã·åã¯
ããã²ã³ãæããããšã®ããããšãã«åã¯ãã³ãŸ
ã€ããã·ãšãã«ãY1ã¯ããã²ã³ãç¡æ©é žæ®åºå
ã¯ææ©é žæ®åºãïœã¯ïŒãïŒã®æŽæ°ãïœã¯ïŒãïŒã®
æŽæ°ã瀺ãïŒã§è¡šããããã¹ã«ãããŠã ååç©ã ïŒ äžè¬åŒ ã§è¡šããããã¹ã«ãã¢ã€ãååç©ãšR2Y1ã§è¡šã
ãããååç©ãšãåå¿ãããããšãç¹åŸŽãšããäž
è¬åŒ ã§è¡šããããã¹ã«ãããŠã ååç©ã®è£œé æ³ã ãã ãR1ãR2ã¯ã¢ã«ãã«ãã·ã¯ãã¢ã«ãã«ã
ã¢ã«ã±ãã«ããã³ãŒã³ç°äžã«çœ®æåºãšããŠã¢ã«ã
ã«ãã¢ã«ã³ãã·åã¯ããã²ã³ãæããããšã®ãã
ã¢ã©ã«ãã«ã眮æåºãšããŠã¢ã«ãã«ãã¢ã«ã³ãã·
åã¯ããã²ã³ãæããããšã®ããããšãã«åã¯ã
ã³ãŸã€ããã·ãšãã«ãY1ã¯ããã²ã³ãç¡æ©é žæ®
åºåã¯ææ©é žæ®åºãïœã¯ïŒãïŒã®æŽæ°ãïœã¯ïŒã
ïŒã®æŽæ°ã瀺ãã ïŒ äžè¬åŒ ã§è¡šããããã¹ã«ãããŠã ååç©ãšäžè¬åŒZY2ã§
è¡šããããååç©ãšãåå¿ãããããšãç¹åŸŽãšã
ãäžè¬åŒ ã§è¡šããããã¹ã«ãããŠã ååç©ã®è£œé æ³ã ãã ãR1ãR2ã¯ã¢ã«ãã«ãã·ã¯ãã¢ã«ãã«ã
ã¢ã«ã±ãã«ããã³ãŒã³ç°äžã«çœ®æåºãšããŠã¢ã«ã
ã«ãã¢ã«ã³ãã·åã¯ããã²ã³ãæããããšã®ãã
ã¢ã©ã«ãã«ã眮æåºãšããŠã¢ã«ãã«ãã¢ã«ã³ãã·
åã¯ããã²ã³ãæããããšã®ããããšãã«åã¯ã
ã³ãŸã€ããã·ãšãã«ãã¯ããã²ã³ãY2ã¯ïŒžãš
ç°ãªãããã²ã³ãæãã¯ç¡æ©é žæ®åºåã¯ææ©é žæ®
åºãã¯éåååã¯ã¢ã«ã«ãªéå±ãïœã¯ïŒãïŒã®
æŽæ°ãïœã¯ïŒãïŒã®æŽæ°ã瀺ãã ïŒ äžè¬åŒ ã§è¡šããããã¹ã«ãããŠã ååç©ã«é žåéãåå¿
ãããããã«HY2ã§è¡šããããååç©ãåå¿ãã
ãããšãç¹åŸŽãšããäžè¬åŒ ã§è¡šããããã¹ã«ãããŠã ååç©ã®è£œé æ³ã ãã ããR1ãR2ã¯ã¢ã«ãã«ãã·ã¯ãã¢ã«ã
ã«ãã¢ã«ã±ãã«ããã³ãŒã³ç°äžã«çœ®æåºãšããŠã¢
ã«ãã«ãã¢ã«ã³ãã·åã¯ããã²ã³ãæããããšã®
ããã¢ã©ã«ãã«ã眮æåºãšããŠã¢ã«ãã«ãã¢ã«ã³
ãã·åã¯ããã²ã³ãæããããšã®ããããšãã«å
ã¯ãã³ãŸã€ããã·ãšãã«ãã¯ããã²ã³ãY2ã¯
ãšç°ãªãããã²ã³æãã¯ç¡æ©é žæ®åºãåã¯ææ©
é žæ®åºããïœã¯ïŒãïŒã®æŽæ°ãïœã¯ïŒãïŒã®æŽæ°
ã瀺ãã
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP1838580A JPS56123977A (en) | 1980-02-15 | 1980-02-15 | Sulfonium compound and its preparation |
US06/231,126 US4340543A (en) | 1980-02-15 | 1981-02-03 | Sulfonium compounds |
GB8103746A GB2070597B (en) | 1980-02-15 | 1981-02-06 | Sulphonium compounds |
CH911/81A CH647771A5 (de) | 1980-02-15 | 1981-02-11 | Sulfoniumderivate. |
AU67234/81A AU522849B2 (en) | 1980-02-15 | 1981-02-12 | Sulfonium compounds |
CA000370898A CA1169080A (en) | 1980-02-15 | 1981-02-13 | Sulfonium compounds |
IT67206/81A IT1172224B (it) | 1980-02-15 | 1981-02-13 | Composti di solfonio |
DE3105303A DE3105303C2 (de) | 1980-02-15 | 1981-02-13 | 2-Tetrahydrofuranyl- und 2-Tetrahydropyranyl-Sulfoniumverbindungen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
ES500077A ES8201568A1 (es) | 1980-02-15 | 1981-02-14 | Procedimiento de preparar compuestos de sulfonio |
NL8100753A NL8100753A (nl) | 1980-02-15 | 1981-02-16 | Sulfoniumverbindingen. |
FR8102956A FR2476084A1 (fr) | 1980-02-15 | 1981-02-16 | Composes de tetrahydrofuranyl-sulfonium et de tetrahydropyranyl-sulfonium, leur preparation et medicaments contenant ces substances |
US06/541,799 US4581372A (en) | 1980-02-15 | 1983-10-14 | Sulfonium compounds |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP1838580A JPS56123977A (en) | 1980-02-15 | 1980-02-15 | Sulfonium compound and its preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS56123977A JPS56123977A (en) | 1981-09-29 |
JPS6145989B2 true JPS6145989B2 (ja) | 1986-10-11 |
Family
ID=11970242
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP1838580A Granted JPS56123977A (en) | 1980-02-15 | 1980-02-15 | Sulfonium compound and its preparation |
Country Status (2)
Country | Link |
---|---|
US (1) | US4340543A (ja) |
JP (1) | JPS56123977A (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0370994B2 (ja) * | 1987-10-02 | 1991-11-11 | Namuko Kk | |
JPH05151207A (ja) * | 1991-11-27 | 1993-06-18 | Sharp Corp | æ å ±åŠçè£ çœ® |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4528383A (en) * | 1982-04-30 | 1985-07-09 | Mobil Oil Corporation | Substituted cyclic and heterocyclic methane sulfonates |
US4504471A (en) * | 1982-09-27 | 1985-03-12 | Fujisawa Pharmaceutical Co., Ltd. | Animal growth promotant and method of use for animal growth |
US4812366A (en) * | 1988-01-25 | 1989-03-14 | Borden Inc. | Viscosity adjustment of ammoniated urea-formaldehyde resin compositions by addition of dried urea-formaldehyde powder |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2562042A (en) * | 1949-09-19 | 1951-07-24 | American Home Foods Inc | Tetrahydropyran-sulfide compounds |
US3455956A (en) * | 1965-02-24 | 1969-07-15 | Takeda Chemical Industries Ltd | Dialkyl-sulfoxides and dialkyl-sulfones |
-
1980
- 1980-02-15 JP JP1838580A patent/JPS56123977A/ja active Granted
-
1981
- 1981-02-03 US US06/231,126 patent/US4340543A/en not_active Expired - Lifetime
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0370994B2 (ja) * | 1987-10-02 | 1991-11-11 | Namuko Kk | |
JPH05151207A (ja) * | 1991-11-27 | 1993-06-18 | Sharp Corp | æ å ±åŠçè£ çœ® |
Also Published As
Publication number | Publication date |
---|---|
US4340543A (en) | 1982-07-20 |
JPS56123977A (en) | 1981-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2415849C2 (ru) | СпПÑПб пПлÑÑÐµÐœÐžÑ ÐžÐŒÐ°ÑОМОба в вОЎе ÑвПбПЎМПгП ПÑÐœÐŸÐ²Ð°ÐœÐžÑ ÐžÐ»Ðž в вОЎе кОÑлПÑМП-аЎЎОÑОвМПй ÑПлО | |
EP3848367A1 (en) | Tricyclic compounds acting on crbn proteins | |
CA3016826C (en) | Salt of pyridinyl amino pyrimidine derivative, preparation method therefor, and application thereof | |
KR102142797B1 (ko) | íŒëŠ¬ëëìë¯žë žíŒëŠ¬ë¯žë ì ë첎ì ë©ì€ë ìŽíž ìŒì ê²°ì ì§ íí, ê·žì ì ì¡° ë°©ë², ë° ê·žì ì©ë | |
EP3686199B9 (en) | Fused ring derivative as a2a receptor inhibitor | |
RU2730500C2 (ru) | ÐÑПОзвПЎМПе Ñ ÐžÐœÐ°Ð·ÐŸÐ»ÐžÐœÐŸÐœÐ°, ÑпПÑПб егП пПлÑÑеМОÑ, ÑаÑЌаÑевÑОÑеÑÐºÐ°Ñ ÐºÐŸÐŒÐ¿ÐŸÐ·ÐžÑÐžÑ Ðž пÑÐžÐŒÐµÐœÐµÐœÐžÑ | |
KR20130046436A (ko) | ìëë¡ê² ìì©ì²Ž êžžíì , íìì ë¡ì ì¬ìŽíŽëŠ n,n''-ë€ìŽì늎í°ì€ì°ë ì ë° n,n''-ë€ìŽì늎ì°ë ì, ìŽì ì ì¡°ë°©ë² ë° ìŽì ì©ë | |
EP4032890A1 (en) | Heterocyclic amide compound, pharmaceutically acceptable salt thereof, and preparation method therefor and use thereof | |
JPH08337584A (ja) | çž®åå ç°åŒã¢ããååç©ããããå«æããå»è¬åã³ãã®è£œæ³ | |
EP0148094A2 (en) | Anti-tumor agent comprising an O-benzylidene-L-ascorbic acid or a salt thereof, and the production of the latter compound | |
US20240132515A1 (en) | Toxin molecule suitable for antibody-drug conjugate | |
US20120309990A1 (en) | Processes for the Purification of Lubiprostone | |
JPS6145989B2 (ja) | ||
US3825571A (en) | Mycophenolic acid derivatives | |
WO2023143147A1 (zh) | äžç§ååªå¹¶å¡å¶é ®ç±»ååç©ãå ¶è¯ç©ç»åç©ååºçš | |
KR100339115B1 (ko) | ê²°ì ì±3-(4-í¥ì€ì¥ì-1,2,5-í°ìëìì¡ž-3-ìŒ)-1,2,5,6-í ížëŒíìŽëë¡-1-ë©ížíŒëŠ¬ë(+)l-íìŽëë¡ê²í륎ížë ìŽíž,ìŽìì ì¡°ë°©ë²ë°ìŽë¥Œí¬íšíëìœì íì ì¡°ì±ë¬Œ | |
AU2005318227B2 (en) | Stereoselective process and crystalline forms of a camptothecin | |
WO2015184405A1 (en) | Aromatic compounds, compositions and uses thereof | |
JPH0370700B2 (ja) | ||
CN114853736B (zh) | å ·ætrkæå¶æŽ»æ§çååç©ãå¶å€æ¹æ³ãç»åç©åå ¶çšé | |
WO2023116763A1 (zh) | äžç§ååªç±»ååç©ãå ¶è¯ç©ç»åç©ååºçš | |
WO2024027695A1 (zh) | äœäžºher2æå¶åçååç© | |
KR840000910B1 (ko) | ì í¬ë íí©ë¬Œì ì ì¡°ë°©ë² | |
JPH037227A (ja) | ïŒâïœïœâïŒã¬ã»ãã¿æ®æå€ | |
TW202136243A (zh) | Zesteå¢åŒ·ååæºç©2æå¶ååå ¶çšé |